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Anticancer Potential of the Triterpenic Fraction of Eucalyptus Bark Extracts in 
Colorectal Cancer Cells 
ABSTRACT 
Cancer is one of the leading causes of death worldwide, being the colorectal cancer the 
third most occurring cancer in developed countries. The search for promising natural anticancer 
compounds is exponentially increasing, with the exploitation of new sources that were 
disregarded. Eucalyptus nitens crops are used in Portugal mainly by the pulp and paper 
industries, which produce substantial bark residues with no add-value use. They can, however, 
be an interesting source of triterpenic compounds. In this study, the potential anticancer effect of 
a lipophilic crude extract (CE) of E. nitens, a fraction of this more enriched in triterpenoids (F2), 
as well as their main isolated compounds, betulinic acid (BiA) and betulonic acid (BoA), was 
studied in the colorectal cancer cells. All test extracts/compounds showed potent anticancer 
effects based on cell viability, colony forming and migration assays. The F2 extract was shown to 
be two times more potent than the CE (IC50s of 1.3 µg/ml and 2.2 µg/ml, respectively), whereas 
BoA was about four times more potent than BiA (IC50s of 0.8 µM and 3.9 µM, respectively). The 
anticancer effects of the extracts/compounds were shown to be dependent both on inhibition of 
cell proliferation, as shown by the induction of cell cycle arrest assessed by flow cytometry, and 
on induction of cell death, as measures by the PI staining. At the higher concentrations tested, 
apoptosis was a contributor to the cell death. Interestingly, contrarily to their IC50s, BiA was a 
more potent inducer of apoptosis than BoA. Apoptosis was triggered by the intrinsic mitochondria 
pathway, probably through JNK activation but not through p53, since its levels were remarkably 
decreased by all the extracts/compounds. At lower doses of E. nitens extracts and tested 
triterpenoids, a non-apoptotic cell death was present, which could be mediated through a 
metabolic crisis, due to the significant activation of the AMPK energy-sensing regulator. This work 
shows the potential use of the wasted bark of E. nitens as an interesting source of potent natural 
anticancer triterpenoids against colorectal cancer cells. 
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Potencial Anticancerígeno da Fração Triterpénica de Extratos da Casca de 
Eucalipto em Células do Carcinoma Colorectal 
RESUMO 
O cancro é uma das maiores causas de morte mundial, sendo o cancro colorectal o terceiro 
tipo de cancro com maior ocorrência nos países desenvolvidos. A procura de compostos 
anticancerígenos naturais promissores está a aumentar exponencialmente, com a exploração de 
novas fontes que eram desconsideradas. Em Portugal as plantações de eucalipto são sobretudo 
utilizadas pelas indústrias de polpa e papel, e uma vez que a casca desta árvore não é utilizada no 
processo, produzem-se quantidades substanciais de resíduos que não são utilizados para fins com 
alto valor económico. Estes resíduos podem, no entanto, ser uma fonte interessante de compostos 
triterpénicos. Neste estudo, o potencial efeito anticancerígeno de extratos lipofílicos de Eucalyptus 
nitens, um bruto (CE) e um fraccionado (F2) mais enriquecido em triterpenóides, bem como os seus 
compostos principais ácido betulínico (BiA) e ácido betulónico (BoA), foram estudados nas células 
HCT116 do carcinoma colorectal. Todos os extratos/compostos testados demonstraram possuir 
efeitos anticancerígenos potentes, tal como observado nos ensaios de viabilidade celular, de 
formação de colónias e de migração celular. Foi demonstrado que o extrato F2 é duas vezes mais 
potente que o CE (IC50s de 1.3 µg/ml e 2.2 µg/ml, respectivamente), enquanto que o BoA foi cerca 
de quatro vezes mais potente que o BiA (IC50s de 0.8 µM e 3.9 µM, respectivamente). Também se 
verificou que os efeitos anticancerígenos dos extratos/compostos são dependentes quer da inibição 
da proliferação celular, como demonstrado pela indução de interrupção no ciclo celular avaliado por 
citometria de fluxo, quer da indução da morte celular, medido pela marcação por iodeto de propídio. 
Nas concentrações mais altas testadas, houve uma contribuição da apoptose para a morte celular 
encontrada. Contrariamente aos valores de IC50s, o BiA foi um indutor de apoptose mais potente que 
o BoA. A apoptose foi desencadeada pela via de sinalização intrínseca mitocondrial, provavelmente 
através da ativação da via JNK mas não através do p53, visto que os seus níveis foram 
marcadamente diminuídos pelos extratos/compostos. A doses mais baixas dos extratos de E. nitens 
e dos triterpenóides testados, também ocorreu morte celular mas de uma forma independente de 
apoptose, a qual pode ter sido mediada por uma crise metabólica, em virtude da ativação 
significativa observada da via AMPK. Os resultados deste trabalho sugerem uma potencial utilização 
valorizada da casca de E. nitens como uma fonte de potentes triterpenóides naturais com atividade 
anticancerígena contra células do carcinoma colorectal. 
 
ix 
 
INDEX 
 
Acknowledgments ……………………………………………………………………………………………………..iii 
Abstract ……………………………………………………………………………………………………………………v 
Resumo …………………………………………………………………………………………………………………..vii 
Abbreviations ……………………………………………………………………………………………………………xi 
List of Figures and Tabels….………………………………………………………………………………………..xv 
Introduction ……………………………………………………………………………………………………………1 
1. Cancer ………………………………………………………………………………………………………….3 
1.1. Colorectal Cancer …………………………………………………………………………………….4 
2. Cancer Cell Signaling ………………………………………………………………………………………6 
2.1. MAP Kinase Pathways ……………………………………………………………………………….7 
2.1.1. ERK Pathway …………………………………………………………………………………7 
2.1.2. JNK and p38 Pathways …………………………………………………………………..8 
2.2. Apoptosis ………………………………………………………………………………………………..9 
2.2.1. The Intrinsic Mitochondrial Pathway …………………………………………………..9 
2.2.2. The Extrinsic Death Receptors Pathway …………………………………………….10 
2.2.3. Role of p53 in Apoptosis ………………………………………………………………11 
3. Eucalyptus spp. …………………………………………………………………………………………….12 
3.1. Eucalyptus nitens ……………………………………………………………………………………12 
3.2. Eucalyptus Pulp Residues Exploitation ………………………………………………………..13 
4. Natural Compounds ………………………………………………………………………………………14 
4.1. Terpenic Compounds ………………………………………………………………………………15 
4.1.1. Triterpenic Compounds …………………………………………………………………15 
4.1.1.1. Betulinic Acid ………………………………………………………………………..16 
4.1.1.2. Betulonic Acid ……………………………………………………………………….19 
4.1.1.3. Ursolic Acid …………………………………………………………………………..20 
4.1.1.4. Oleanolic Acid ……………………………………………………………………….20 
x 
 
Objectives of the Work …………………………………………………………………………………………22 
Materials and Methods ………………………………………………………………………………………..23 
1. Chemicals ……………………………………………………………………………………………………25 
2. Eucalyptus nitens Extracts and Triterpenoids ……………………………………………………..25 
3. Antibodies ……………………………………………………………………………………………………25 
4. Cell Culture ………………………………………………………………………………………………….26 
5. MTT Reduction Assay …………………………………………………………………………………….26 
6. Anchorage-Dependent Colony Forming ……………………………………………………………..27 
7. Cell Death Analysis by Propidium Iodide (PI) Staining …………………………………………..27 
8. Nuclear Condensation ……………………………………………………………………………………28 
9. Cell Cycle Analysis ………………………………………………………………………………………..29 
10. Migration Assay (Wound Healing) …………………………………………………………………….29 
11. Western Blotting ……………………………………………………………………………………………30 
12. Statistics ……………………………………………………………………………………………………..30 
Results and Discussion …………………………………………………………………………………………31 
1. Triterpenic Acids-Enriched Extracts from E. nitens Possess Anticancer Activity Against 
HCT116 Cells ………………………………………………………………………………………………34 
2. Apoptosis Contributes to the Cell Death Induced by E. nitens Extracts and their Main 
Lupane Acids in HCT116 Cells ………………………………………………………………………..42 
3. Eucalyptus nitens Extracts and their Main Lupane Acids Induce JNK and AMPK Siganlling 
in HCT116 Cells …………………………………………………………………………………………..47 
4. Eucalyptus nitens Extracts and their Main Lupane Acids Induce Cell Cycle Arrest in 
HCT116 Cells ……………………………………………………………………………………………...49 
Conclusions and Future Perspectives …………………………………………………………………..51 
1. Conclusions …………………………………………………………………………………………………53 
2. Future Perspectives ……………………………………………………………………………………….55 
References ……………………………………………………………………………………………………….….57 
xi 
 
ABBREVIATIONS 
  
5-FU    5-Fluorouracil 
AIF    Apoptosis-inducing factor 
Akt    Protein kinase B 
AMPK    5’ adenosine monophosphate-activated protein kinase 
ANOVA   Analysis of variance 
Apaf-1    Apoptotic protease activating factor 1 
APC    Antigen-presenting cell 
β-TrcP    Beta-transducin repeat containing E3 ubiquitin protein ligase 
BAD    Bcl-2-associated death promoter 
BAK    Bcl-2 homologous antagonist killer 
BAX    Bcl-2-associated protein 
Bcl-2    B-cell lymphoma 2 
Bcl-Xl    B-cell lymphoma-extra large 
BH3    Bcl-2 homology 3 
BiA    Betulinic acid 
Bid    BH3 interacting-domain death agonist 
Bik    Bcl-2-interacting killer 
BoA    Betulonic acid 
BRAF    V-raf murine sarcoma viral oncogene homolog B1 
BSA    Bovine serum albumin 
CD95    Cluster of differentiation 95 
CE    Crude extract 
COX2    Cyclooxygenase 
CRC    Colorectal cancer 
DCC    Deleted in colorectal cancer 
DMSO    Dimethyl sulfoxide 
DNA    Deoxyribonucleic acid 
DR    Death receptor 
ERK    Extracellular-signal-regulated kinase 
F2    Fraction 2 
xii 
 
FADD    Fas-associated protein with death domain 
FAP    Familial adenomatous polyposis 
FBS    Fetal bovine serum 
HDM2    Human double minute 2 homolog 
HIV    Human immunodeficiency virus 
HNPCC   Hereditary nonpolyposis colorectal cancer 
IAP    Inhibitor of apoptosis 
JNK    c-Jun N-terminal kinase 
KRAS    V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
LT    Lupane triterpenoids 
MAPK    Mitogen-activated protein kinase 
MAPKK   MAPK kinase 
MAPKKK   MAPKK kinase 
MCC    Mutated in colorectal cancer 
MMP    Mitochondrial membrane permeabilization 
NF-kB    Nuclear factor kappa-light-chain-enhancer of activated B cells 
Noxa    Phorbol-12-myristate-13-acetate-induced protein 1 
OA    Oleanolic acid 
OMM    Outer mitochondrial membrane 
p53    Protein 53 
PARP1   Poly (ADP-ribose) polymerase 1 
PBS    Phosphate-buffered saline 
PI    Propidium iodide 
PI3K    Phosphoinositide 3-kinase 
PMSF    Phenylmethylsulfonyl fluoride 
PTEN    Phosphatase and tensin homolog 
Puma    p53 upregulated modulator of apoptosis 
RIPA    Radioimmunoprecipitation assay 
RPMI    Roswell park memorial institute medium 
RTK    Receptor tyrosine kinase 
SAPK    Stress activated protein kinases 
SDS    Sodium dodecyl sulfate 
xiii 
 
SEM    Standard error of the mean 
SMAC    IAP-binding mitochondrial protein 
SMAD4   SMAD family member 4 
TGFβ-RII   Transforming growth factor beta receptor II 
TRAIL   TNF-related apoptosis-inducing ligand 
TREN   Triterpenic-enriched E. nitens extracts 
UA    Ursolic acid 
 
xv 
 
LIST OF FIGURES AND TABLES 
 
Figure 1. APC/β-catenin signalling in colorectal cancer. ..........................................................5 
Figure 2. Schematic representation of MAPK/ERK and PI3K/Akt pathways in relation with cell 
proliferation and apoptosis. ……………………………………………………………………….………6 
Figure 3. Schematic representation of the ERK pathway. ……………………………………………….7 
Figure 4. Scheme of the intrinsic mitochondrial pathway of apoptosis, with release of 
cytochrome c ……………………………………………………………………………………………….10 
Figure 5. Scheme of the extrinsic death receptor pathway of apoptosis …………………………….11 
Figure 6. E. nitens in an industrial plantation in Australia. …………………………………………..…13 
Figure 7. Chemical structure of betulinic acid. …………………………………………………………….16 
Figure 8. Chemical structure of betulonic acid. …………………………………………………………...19 
Figure 9. Chemical structure of ursolic acid. ……………………………………………………………….20 
Figure 10. Chemical structure of oleanolic acid. ………………………………………………………….21 
Figure 11. Representative images of the flow cytometry for cell death measurement ………….28 
Figure 12. Effect of tested extracts and compounds in HCT116 cells viability ……………………35 
Figure 13. Representative images of the effect of different concentrations of tested extracts and 
compounds on the morphology of HCT116 cells …………………………………………………36 
Figure 14. Effect of tested extracts and compounds in HCT116 cell viability and cell death 
along the time of incubation ………………………………………………………………………..….38 
Figure 15. Effect of tested extracts and compounds in the ability to inhibit colony forming in 
HCT116 cells ……………………………………………………………………………………………….40 
Figure 16. Effect of tested extracts and compounds in the ability of HCT116 cells to migrate..41 
xvi 
 
Figure 17. Effect of tested extracts and compounds in the presence of nuclear condensation in 
HCT116 cells ……………………………………………………………………………………………….43 
Figure 18. Effect of tested extracts and compounds on the levels of apoptosis and kinases 
markers using western blot ……………………………………………………………………………..46 
Figure 19. Effect of tested extracts and compounds in the cell cycle of HCT116 cells …………50 
Figure 20. Scheme representing the possible mechanisms of action of the anticancer effect of 
tested extracts and compounds in HCT116 cells …………………………………………………54 
 
Table 1. Chemical composition of the E. nitens crude extract and of the triterpenic enriched 
fraction 2 ………………………………………………………………………………………………….…26 
 INTRODUCTION 
 
INTRODUCTION 
 
3 
 
1. CANCER 
Cancer is one of the leading causes of death in the world. In 2005, the global cancer 
incidence was of 11 million with over than 7.6 million of deaths, and it is prospected that by 
2030 the incidence grows to 15.5 million with 11.5 million of deaths (Amin et al., 2009).  
Although being a very common disease, cancer is mainly preventable (Amin et al., 
2009). Only 5 to 10% of all cancers are completely hereditary, while several external and 
environmental factors are known to increase significantly the risk of this disease, such as 
smoking, poor diet (fatty foods and alcohol), exposure to radiation, obesity, excessive sunlight 
exposure, viruses, environmental pollutants and certain infections (Anand et al., 2008). 
Cancer is a complex disease that can develop in human beings over a number of years 
(Dzubak et al., 2005). In the development of cancer a normal cell is transformed in a cancer cell 
through a process called carcinogenesis. During this process it is necessary that the genes 
regulating cell differentiation and growth undergo failure or alteration (Dzubak et al., 2005). 
These genes are divided into oncogenes, which are responsible for the promotion of cell growth 
and proliferation; and into tumour suppressor genes, like p53, that inhibit cell division and 
survival. The carcinogenic process is characterized by three phases of development, which 
ultimately leads to cancer formation and growth. These steps are initiation/mutation, promotion 
and progression/metastasis. The normal cell suffers damage, leading to mutation of DNA which 
no longer undergoes DNA repair or undergoes defective DNA repair resulting in unrestrained 
proliferation (initiation) (Dzubak et al., 2005). The continuous proliferation facilitates the 
occurrence of even more mutations originating a mass of cells that no longer have their normal 
abilities and only proliferate (promotion). The growth of the tumour is aided by angiogenesis, 
which not only provides nutritients to the tumour, but also allows cancerous cells to migrate to 
other tissues via the circulatory system, metastasizing the tumour (progression), which normally 
is lethal. The most noticeable change in these cells is their ability to avoid programmed cell death 
(apoptosis), leading to the tumour growth (Dzubak et al., 2005). Besides the resistance to 
apoptosis, sustainable cell proliferation without stimulating signals, promotion of angiogenesis as 
well as the ability to tissue invasion and establishment of metastasis, other characteristics 
(“hallmarks”) of cancer include evasion to growth suppressors, limitless proliferative potential, 
local promotion of inflammation, genome instability and mutation, evasion of immune system 
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and deregulation of metabolic pathways (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 
2011). 
Chemotherapy is a standard treatment to cancer, especially after surgical tumour 
removal (Saxena et al., 2006; Drag et al., 2009). Considering that chemotherapy’s main aim is 
to eliminate the remaining cancer cells present in the organism, most of the times the success of 
this treatment determines the final success of the recovery (Drag et al., 2009). The efficacy of 
this treatment has improved greatly in the last decade, but the treatment for this disease still 
faces a very high mortality rate (Santos et al., 2011). Also, the toxic adverse effects of the used 
drugs lead to severe life quality threats and 80% of the patients undergoing this treatment die due 
to the resistance of cancer cells to drugs. Therefore, the development of new potent, non-toxic 
and non-resistant anticancer agents is crucial to more effective therapies (Fulda and Debatin, 
2000; Jung et al., 2007; Drag et al., 2009; Santos et al., 2011). 
 
1.1.   COLORECTAL CANCER (CRC) 
Colorectal cancer (CRC) is the third most occurring cancer (8.5% of all cancers (Jung et 
al., 2007)) in the world and one of the leading causes of death in the developed countries (with 
65.500 deaths worldwide (Rajendran et al., 2008)), being uncommon in most non-developed 
countries (Jung et al., 2007; Rajendran et al.; 2008; Xavier et al., 2009a; Chintharlapalli et al., 
2011). Therefore, the incidence rates of CRC are highly variable in different regions of the world 
and the differences of the occurrence of this disease in migrants suggests that environmental 
factors and diet play a major role in the development of this cancer (Chintharlapalli et al., 2011).  
CRC can be divided into sporadic, familial and inherited. The sporadic represents 50 to 
60% of CRC and there is no evidence of the disease in family history, being more common in 
individuals with age over 50. The familial account for 30 to 40% of all the cases, and normally the 
patient has a history of CRC in the family (Souglakos, 2007). The inherited CRC represents 4 to 
6% and can be further divided depending on whether there are or not colonic polyps: familial 
adenomatous polyposis (FAP) on the presence of those and hereditary nonpolyposis colorectal 
cancer (HNPCC) or Lynch Syndrome on their absence (Rustki, 2007). 
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The initial event of 
carcinogenesis in the colon epithelium 
is mostly the accumulation of a genetic 
alteration in the antigen-presenting cell 
(APC) gene, which is part of the Wnt 
signalling pathway (Fig.1). This 
mutation disables the production of the 
APC protein leading to accumulation of 
the β-catenin protein, which translocate 
to the nucleus, leading to the activation 
of transcription of genes that, at high 
levels, cause cancer (Souglakos, 2007). 
However, mutation in this pathway are 
not the only ones necessary for the cell 
to become cancerous; other mutations 
must take place, such as in the TP53 
gene that is responsible for killing the 
cell if there is any defect in the Wnt pathway. Genetic alteration in the transforming growth factor 
β receptor II (TGFβ-RII), phosphatase and tensin homologue (PTEN), cyclooxygenase 2 (COX2), 
deleted in colorectal cancer (DCC), mutated in colorectal cancer (MCC), SMAD4, 
phosphoinositide 3-kinase (PI3K), v-raf murine sarcoma viral oncogene homolog 1 (BRAF), v-Ki-
ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and Bcl-2-associated x protein (BAX) 
genes have also been found to play a role in CRC (Takami et al., 1995; Soreide et al., 2006; 
Souglakos, 2007). 
Complete remission of CRC by sirurgical removal is possible. Nevertheless, 
approximately 50% of the cases eventually develops incurable metastesis, normally in the liver, 
even when coupled with adjuvant treatment (Jung et al., 2007; Rajendran et al., 2008). 
Therapies for gastrointestinal cancers have many defficiencies since the general response to 
treatment is low to moderate, the life extension is, on most cases, only of two to three months, 
there is a high toxicity to normal cells, high percentages of relapse cases and multiple drug 
resistances observed (Rajendran et al., 2008). Chemotherapy based on 5-fluorouracil (5-FU) is 
the standard treatment over the last forty years to extend patients survival when the CRC is 
Figure 1 – APC/β-catenin signalling in CRC. (OFF) The APC 
protein is synthesised, β-catenin is phosphorylated and occurs 
ubiquitin-mediated degradation of β-catenin by the beta-
transducin repeat containing E3 ubiquitin protein ligase (β-
Trc)P. (ON) The APC protein is not produced, occurring 
accumulation of β-catenin which enters the nucleus, enabling 
transcription. [http://www.umcutrecht.nl] 
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metastasized. However, the response rate of CRC metastasis to 5-FU is only of approximately 
20% mainly due to cancer cell resistance to this drug (Jung et al., 2007; Rajendran et al., 2008; 
Xavier et al., 2011). To overcome this resistance two new drugs were developed, Irinotecan and 
Oxalipatin, that, combined with 5-FU, are able to overcome some of the drug resistance, 
increasing the survival of the patients (Rajendran et al., 2008; Xavier et al., 2011). Nevertheless, 
this improvement of efficiency is not observed in all patients (Xavier et al., 2011). 
 
2.   CANCER CELL SIGNALING  
The process of carcinogenesis encompasses a series of genetic mutations that leads to 
modifications in very important biological pathways related with cell proliferation, survival and cell 
death, leading to dramatic changes in the cell.  
Some of them that are frequently activated in CRC are the MAPK/ERK and PI3K/Akt 
signalling pathways (Fig.2) which also 
determine treatment response. These 
pathways are usually activated by 
mutations either on KRAS or BRAF genes. 
Mutation on KRAS gene can lead to the 
activation of MAPK/ERK and/or PI3K/Akt 
pathways, whereas mutations on BRAF 
gene activates MAPK/ERK pathway only. 
These mutations are found in over 50% of 
CRC cases and occur alternately with 32% 
of cases being due to KRAS gene mutation 
and 14% due to BRAF gene mutation 
(Xavier et al., 2009a; Xavier et al., 2009b; 
Xavier et al., 2012). 
 
 
 
Figure 2 – Schematic representation of MAPK/ERK and 
PI3K/Akt pathways in relation with cell proliferation and 
apoptosis. RTK – receptor tyrosine kinases 
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2.1   MAP KINASE PATHWAYS  
Mitogen-activated protein kinases (MAPK) are a family of ubiquitous proline-directed, 
protein-serine/threonine kinases, which participate in signal transduction pathways that control 
several intracellular events (Pearson et al., 2001), including embryogenesis, inflammatory 
response, cell differentiation, cell proliferation and cell death (Chen et al., 2001). They help 
mediate diverse processes from transcription of proto-oncogenes to programmed cell death 
(Cobb, 1999). The three major and best-known subfamilies of MAPKs are the extracellular-signal-
regulated kinase (ERK) 1/2, which conveys growth signals from the RAS/RAF pathway and 
receptor kinases, and the c-Jun N-terminal kinase (JNK) 1/2/3 and the p38 MAP kinase (p38) 
α/β/γ/δ, which relay various stress signals. 
The MAPK are catalytically inactive in their base form, and require, in order to become 
active, phosphorylation events in their activation loops. The activity is regulated by a cascade of 
activations where MAPKs are phosphorylated by the MAPK kinase (MAPKK), which is, in turn, 
phosphorylated by MAPKK kinase (MAPKKK) (Cobb, 1999; Chen et al., 2001; Pearson et al., 
2001; Cuevas et al., 2007). The MAPKKK are not specific to one MAPKK, being able to regulate 
multiples MAPKKs, and leading to the activation of different subfamilies of MAPK, like the 
mentioned ERK, JNK and p38 (Cuevas et al., 2007). 
 
2.1.1.   ERK PATHWAY  
The MAPK/RAF/ERK pathway is one of the 
most important signalling networks that control 
proliferation, differentiation and cell survival (Kolch, 
2000), and this cascade is activated by a variety of 
receptors involved in growth and differentiation 
(McCubrey et al., 2006). When ERK is improperly 
activated it contributes to malignant transformation.  
Raf is a serine/threonine protein that can be 
found in three forms: a-Raf, b-Raf and c-Raf, that are 
recruited to the membrane, bind to Ras, being 
Figure 3 – Schematic representation of the 
ERK pathway. [Image from Kolch, 2000] 
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subjected to phosphorylations and dephosphorylations promoting the activation of Raf. After Ras 
activation, a MAPKKK phosphorylates two MAPKK proteins, MAPK 1 and 2, which activates the 
MAPK ERK 1 and 2 (Fig.3). The activated ERK acts on cytosol by activating NF-kB, and on the 
nucleus by promoting the phosphorylation of several transcription factors. 
 
2.1.2.   JNK AND P38 PATHWAYS 
JNK and p38 are protein kinases (also called stress-activated protein kinases – SAPKs) 
that are activated by environmental stresses, inflammatory cytokines, growth factors, mitogens, 
oncogenes and inducers of cell differentiation and morphogenesis (Bogoyevitch et al., 2010). 
These two pathways are frequently deregulated in cancer, including in CRC (Xavier et al., 2012). 
They function in a cell context-specific and cell type-specific manner to integrate signals that 
affect proliferation, differentiation, survival and migration (Wagner and Nebreda, 2009).  
The JNK protein kinase play a critical role in the extrinsic as well as in the intrinsic 
(mitochondrial) apoptotic pathways, by upregulating pro-apoptotic genes (Dhanasekaram and 
Reddy, 2011; Xavier et al., 2013). They are encoded by three genes: JNK1, JNK2 and JNK3. The 
transcripts of these genes are alternatively spliced to yield four JNK1 isoforms, four JNK2 
isoforms and two JNK3 isoforms. JNK1 and JNK2 are products of alternative splicing of a single 
gene and so are expressed in several tissues, while JNK3 is specifically expressed in the brain 
(Wagner and Nebreda, 2009). The three JNKs play a vital regulatory role in the responses to 
several stresses, neural development, inflammation and apoptosis (Dhanasekaram and Reddy, 
2011). 
The p38 MAPK subfamily is involved in cell differentiation, cell migration inhibition of cell 
cycle progression, apoptosis and autophagy (Zarubin and Han, 2005; Ashwell et al., 2006). It 
has been identified four p38 MAPK: p38-α, p38-β, p38-γ and p38-δ, which are encoded by 
MAPK14, MAPK11, MAPK12 and MAPK13, respectively. The p38-α is the most abundant one, 
being present in most cell types (Wagner and Nebreda, 2009). 
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2.2.   APOPTOSIS  
Apoptosis, which in Greek literally means “falling away”, is an intrinsic programmed cell 
death process highly conserved in different species, that occurs in multicellular organisms as a 
natural and organized process, which plays an important role in the embryonic development and 
in the balance of human tissues by adjusting the involved physiologic processes (Fulda, 2008; 
Fulda and Kroemer, 2009; Wu et al., 2010; Yadav et al., 2010). Through apoptosis, the 
organism is able to maintain homeostasis, by the elimination of damaged or unnecessary cells 
without local inflammation due to leakage of cells’ contents. Therefore, any cell that has 
abnormalities such as DNA damage, oncogene activation, nutrition deficiency or hypoxia, can be 
eliminated without damage to the surrounding cells (Yadav et al., 2010). Apoptosis is 
characterized by distinct morphological characteristics such as cellular shrinkage, chromatin 
condensation, plasmatic membrane blebbing, oligonucleosomal DNA fragmentation and collapse 
of the cell in smaller units (formation of apoptotic bodies) (Liu et al., 2004; Santos et al., 2011). 
Since apoptosis is involved in the regulation of many physiological processes, a deficient 
apoptosis signalling may contribute to a variety of different pathological conditions (Fulda and 
Kroemer, 2009). Cancer is one of such pathologies, since cancer cells are able to escape 
apoptosis, allowing tumours to grow rapid and uncontrollably (Yadav et al., 2010). 
There are two different pathways through which apoptosis can be initiated: the intrinsic 
pathway that involves the mitochondria and the extrinsic pathway that involves the plasmatic 
membrane via death receptors (DR), both of them inducing activation of proteolytic enzymes 
called cysteine aspartic acid specific proteases (caspases) (Fulda, 2008; Fulda and Kroemer, 
2009).   
 
2.2.1.   THE INTRINSIC MITOCHONDRIAL PATHWAY  
The intrinsic pathway (Fig.4) can be activated by different stress stimuli, such as heat 
shock, ultraviolet radiation or DNA damage. The permeabilization of the mitochondrial 
membranes is frequently the decisive event that delimits the boundary between survival and 
death (Fulda et al., 1997; Fulda and Debatin, 2000; Liu et al., 2004; Fulda and Kroemer, 2009). 
The B-cell lymphoma 2 (Bcl-2) family proteins are regulators of apoptosis and comprise both anti-
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apoptotic members, such as Bcl-2, Bcl-Xl and McH that inhibits the permeabilization of the 
mitochondrial membrane, and pro-apoptotic member, such as BAX, BAK, BAD, Bik, Bid, Puma, 
Noxa and BH3 that permeabilize the mitochondrial membrane (Fulda et al., 1997; Yadav et al., 
2010). Bax and Bak proteins can be upregulated by the tumour suppressor protein p53 (Yadav et 
al., 2010), be inserted in the outer 
mitochondrial membrane (OMM), 
permeabilizing it and causing the release of 
cytochrome c, apoptosis inductor factor (AIF) 
and second mitochondria derived activator of 
caspases (SMACs) (Fulda and Debatin, 2000; 
Dzubak et al., 2005; Fulda, 2008; Fulda and 
Kroemer, 2009; Yadav et al., 2010). 
Imbalances in the ratio of the anti-apoptotic 
versus pro-apoptotic Bcl-2 proteins regulate the 
permeabilization of the OMM (Fulda et al., 
1997; Rzeski et al., 2006; Fulda and Kroemer, 
2009; Wu et al., 2010). 
After its release, cytochrome c interacts with the apoptotic protease activating factor-1 
(Apaf-1) and recruits pro-caspase-9 to stimulate the formation of the apoptosome, which will lead 
to the cleavage and activation of caspases 9 that will mediate the activation of caspases 3, 6 and 
7 to promote apoptosis (Fig.4). The SMAC promotes activation of caspases by deactivating 
inhibitors of apoptosis proteins (IAPs), allowing apoptosis to continue; and the AIF induces 
apoptosis without caspases involvement (Fulda, 2008; Fulda and Kroemer, 2009; Yadav et al., 
2010). 
 
2.2.2.   THE EXTRINSIC DEATH RECEPTORS PATHWAY  
In the extrinsic pathway (Fig.5), apoptosis is triggered by activation of pro-apoptotic death 
receptors, such as CD95 or TNF-related apoptosis-inducing ligand (TRAIL) receptors through its 
ligands cognate. The stimulation of the DR leads to receptor trimerization, recruitment of adaptor 
molecules, such as fas-associated protein with death domain (FADD), and activation of caspase 8 
Figure 4 – Scheme of the Intrinsic Mitochondrial 
Pathway, with release of cytochrome c. [Image from 
http://www.biooncology.com] 
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initiator, which spreads the death signal to effector 
caspases like caspases 3, 6 and 7 (Fulda, 2008; Yadav 
et al., 2010). 
At this point, both intrinsic and extrinsic 
pathways converge with the activation of the same 
caspases. Also, caspase 8, through its mediated 
cleavage, activates the BH3 interacting-domain death 
agonist (Bid) which is translocated to the mitochondria 
to promote cytochrome c release (Fulda, 2008). 
 
 
 
2.2.3. ROLE OF P53 IN APOPTOSIS  
The protein 53 (p53) is a tumour suppressor protein whose activity stops the formation 
of tumours, being considered the “guardian of the genome”. It mediates critical functions in 
cells, such as inhibition of proliferation by induction of cell cycle arrest and induction of apoptotic 
cell death. In normal cells, p53 is usually present at very low levels and it can be activated in 
response to stress, like hypoxia, heat shock and DNA damage agents. Its stability is regulated by 
the E3 ubiquitin ligase and human double minute 2 homolog (HDM2), which mediates the 
ubiquitination of p53 and allows its degradation by the proteosome, maintaining the p53 levels 
low (Chari et al., 2009). 
When activated, p53 translocates to the nucleus where it binds to specific DNA 
sequences elements within the regulatory regions of target gene promoters regulating the 
transcription of several genes related with apoptosis and/or cell cycle (Chari et al., 2009). 
Furthermore, this protein can also activate the apoptotic mechanism through interaction with the 
members of the anti- and pro-apoptotic Bcl-2 family proteins to induce the intrinsic mitochondrial 
pathway (Vaseva and Moll, 2009). 
 
Figure 5 – Scheme of the Extrinsic Death 
Receptor Pathway. [Image from 
http://www.biooncology.com] 
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3.   EUCALYPTUS SPP.   
Eucalyptus spp., from the family Myrtaceae, are evergreen flowering trees (Russell et al., 
1997). This genus consists of approximately 600 species and has a physiological plasticity (it 
supports tropical and temperate climes) that allows some species to propagate in different 
regions of the world (Moura et al., 2012). In spite of this, only fifteen species occur outside 
Australia, and only nine do not occur there, thus eucalyptus is mostly native to Australia. The 
eucalyptus tree has high value mainly because it is a major source of cellulose for paper 
manufacture, being the most common short fibre source for pulpwood in Portugal, Spain, Brazil, 
Chile, South Africa, Japan, among other countries (Pereira et al., 2005; Domingues et al., 2010; 
Domingues et al., 2011b; Moura et al., 2012). It is also very sought for its essential oil, which, 
despite being highly toxic if ingested pure, is a good antiseptic, anti-malarial, industrial solvent 
and insect repellent as well as used as additive for food industry (Russell et al., 1997; Pereira et 
al., 2005; Moura et al., 2012). Eucalyptuses are also valuable for apiculture and the resulting 
honey being studied for their antibacterial activity (Irish et al., 2011). Furthermore, the lipophilic 
extracts from the bark of some eucalyptus (namely Eucalyptus globulus, Eucalyptus 
camaldulensis var. obtusa, Eucalyptus grandis, Eucalyptus maidenii, Eucalyptus urograndis and 
Eucalyptus nitens) are profoundly rich in triterpenic compounds, specially triterpenic acids like 
oleanolic, 3-acetyloleanolic, ursolic, 3-acetyl-ursolic, betulinic, 3-acetylbetulinic and betulonic 
acids, that are valuable bioactive compounds (Siddiqui et al., 2000; Kibblewhite et al., 2001; 
Pereira et al., 2005; Domingues et al., 2010; Domingues et al., 2011a;Domingues et al., 2011b; 
Santos et al., 2011b; Domingues et al., 2012). 
 
3.1.   EUCALYPTUS NITENS   
Eucalyptus nitens (Fig. 6) is a species of fast growth and great development, with a 
natural distribution in small and normally isolated populations. It is a tall to very tall forest tree, 
normally with heights between 40 to 70 meters being able to reach 90 meters and diameter of 1 
to 2 meters. Its juvenile leaves are smooth, orbicular and very fragrant; adult leaves are alternate, 
long, curved, flexible and they set up a high silvery crown when grown in plantations (Tibbits et 
al., 1997). Eucalyptus nitens is also known as Shining Gum, since nitens in Latin means 
shining/bright and this refers to their leaves, buds, bark and fruits that have a distinct glossy.  
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Eucalyptus nitens is mostly planted for industrial 
purposes, given that most of their crops are used to the 
pulp and paper industry (Domingues et al., 2011) due to 
its final pulp properties (Domingues et al., 2011a). The 
most meaningful plantations are in Chile (45%), Australia 
(30%) and South Africa (17%) and can be also found in 
New Zealand, Northern Spain and Portugal. This species 
is normally planted in unsuitable sites for E. globulus 
(the leading eucalyptus planted for the pulp and paper 
industry), because it can tolerate a climate much colder 
and also grows very well at high altitudes, two 
characteristics that E. globulus does not have (Tibbits et 
al., 1997). 
It has been reported that the outer bark of E. nitens contains significant quantities of 
triterpenoids and acetyl derivatives, like ursolic, 3-acetylursolic, betulinic, oleanolic, 3-
acetyloleanolic and betulonic acids (Domingues et al., 2011a; Domingues et al., 2012). 
 
3.2.   EUCALYPTUS PULP RESIDUES EXPLOITATION 
There is a growing interest of performing an integrated exploitation of plant biomass as a 
source of materials, chemicals, fuels and energy in the concept of biorefinery. This approach has 
attracted the interest of agro-forest industries in order to take the maximum value out of their 
crops. In particular to the pulp and paper industries, because it produces substantial quantities of 
residues, especially bark, leaves and fruits, which are simply burned to energy production or left 
behind, this is an example where this biorefinery concept may reach a big success (Pereira et al., 
2005; Domingues et al., 2010; Domingues et al., 2011b).  
These byproducts of the pulp and paper industries may have high valuable compounds 
in their composition and they can be exploited without affecting the industry production and 
minimizing residues formation, being promising sources of bioactive natural chemicals 
(Domingues et al., 2010; Domingues et al., 2011b). So, a more profound study of these non-
used byproducts can contribute to increase the economic value of crops and retrieving valuable 
Figure 6 – E. nitens in an industrial 
plantation in Australia. [Adapted from CSIRO 
Forestry and Forest Products] 
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compounds that would be otherwise discarded (Pereira et al., 2005; Domingues et al., 2011b; 
Santos et al., 2011b). The exploitation of high value low molecular mass compounds, such as 
phytosterols (namely β-sitosterol), lignans and triterpenoids, from industrial byproducts is a 
strategy already implemented in some pulp industries (Domingues et al., 2010), as some of 
these compounds, specially triterpenoids, can be of great interest as anticancer agents. 
The bark of eucalyptus species is among the residues with most interest (Domingues et 
al., 2011b). The bark of different eucalyptus residues left behind by pulp and paper industries 
contains very valuable compounds, namely triterpenoids with great biological activities. The 
compounds extracted from these different species are basically the same, although with different 
proportions. So, E. camaldulensis var. obtusa, E. nitens, E. globulus, E. maidenii, E. urograndis 
and E. grandis are highly rich in triterpenic acids with lupane, ursane and oleane skeletons 
namely ursolic, 3-acetylursolic, oleanolic, 3-acetyloleanolic, betulinic and betulonic acids 
(Kibblewhite et al., 2000; Siddiqui et al., 2000; Pereira et al., 2005; Domingues et al., 2010; 
Domingues et al., 2011a; Domingues et al., 2011b; Santos et al., 2011). Besides triterpenic 
compounds, it can also be found small quantities of fatty acids, fatty alcohols and aromatic 
compounds (Domingues et al., 2011b). 
 
4.   NATURAL COMPOUNDS 
Traditional medicine and diet have been serving humanity throughout the centuries as a 
means of preventing and treating most of chronic diseases (Fulda, 2008; Fulda and Kroemer, 
2009; Yadav et al., 2010; Yi et al., 2010). Natural compounds have been extensively used in the 
treatment of multiple diseases and are of great value for the scientific community, either in its 
natural form or as models to synthetic modification (Rajendran et al., 2008; Yadav et al., 2010). 
These compounds used nowadays in modern medicine exhibit a great chemical diversity and, 
along with its analogues and many others natural products, show the great importance of these 
compounds in the efforts of discovering new drugs (Fulda, 2008; Fulda and Kroemer, 2009; 
Yadav et al., 2010; Yi et al., 2010). The interest in natural compounds has increased over the 
last few years, due to concerns about drug costs and, mainly, due to their security, as natural 
compounds have usually low toxicity. Furthermore, they have high yield, easy obtainment, 
favourable physiological functions, antioxidant activity and are generally accepted as dietetic 
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supplements (Amin et al., 2009; Yadav et al., 2010; Yi et al., 2010), being considered a 
fascinating strategy as therapeutic agents (Bishayee et al., 2011). Over the last decade, many 
bioactive compounds have been identified in plants and human diet and are being developed as 
chemopreventive agents to inhibit, slow down or even reverse the progression of several cancers 
(Amin et al., 2009; Yadav et al., 2010; Bishayee et al., 2011). In fact, the great majority of 
anticancer agents are derived from natural compounds or their analogues (Fulda, 2008; Fulda 
and Kroemer, 2009; Santos et al., 2011). The anticancer activity of natural compounds has been 
partially explained by its ability in triggering cellular death pathways, including apoptosis (Fulda 
and Kroemer, 2009).  
 
4.1.   TERPENIC COMPOUNDS 
One of the groups of natural compounds are terpenes (or terpenoids or isoprenoides) 
that can be divided, according with the number of structural molecules of isoprenes, into mono-, 
sesqui-, di-, sester-, tri-, tetra- and poly-terpenes which create extensive isoprenoides groups. With 
almost 40.000 different terpenes isolated from plants, animals and microbial species they are 
widely found in Nature. They are the biggest natural compound group found in plants (Dzubak et 
al., 2005; Bishayee et al., 2011). Terpenes and its metabolites play a very important role in 
plants defence mechanisms; they protect plants from the constitutive and induced defensive 
responses against insects and environmental stress (Yadav et al., 2010). Among terpenes, the 
triterpenes have recently emerged as an unique group of phytochemicals with multi-functional 
activities (Bishayee et al., 2011). 
 
4.1.1.   TRITERPENIC COMPOUNDS 
Triterpenes, or triterpenoids, are isopentenyl pyrophosphate oligomers metabolites that 
are chemically related to squalene, which is a big group of compounds that have thirty carbon 
atoms arranged in five rings with several oxygen atoms connected. Triterpenes are part of the 
biggest plants compounds group, the Saponins (Yadav et al., 2010; Bishayee et al., 2011). It is 
estimated that there are over 20.000 triterpenes in Nature, and they are predominantly found in 
plants and fruits, being considered one of the most important natural compounds’ class (Dzubak 
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et al., 2005; Kommera et al., 2011; Bishayee et al., 2011; Csuk et al., 2011). Thousands of new 
structures have been described with hundreds of new derivatives being found each year 
(Cichewicz and Kouzi, 2004). The variability of triterpenes in Nature is the result of the evolution 
of a big family of terpene synthase (Yadav et al., 2010). The triterpenes can be subclassified in 
diverse groups including the cucurbitanes, cycloartanes, dammaranes, euphanes, friedelanes, 
holostanes, hopanes, isomalabaricanes, lanostanes, limonoids, lupanes, oleananes, protostanes, 
squalenes, tirucallanes, ursanes and other compounds (Bishayee et al., 2011). In a biological 
perspective the most important triterpenoids structures are the oleananes, ursanes, lupanes, 
dammaranes and euphanes (Dzubak et al., 2005), emphasizing the lupane group that are 
recognized as promising compounds for the development of new bioactive agents (Cichewicz and 
Kouzi, 2004; Kommera et al., 2011; Domingues et al., 2011b). 
Even though for a long time the triterpenes were considered biologically inactive, the 
accumulating evidences of its wide pharmacological activities spectrum along with its low toxicity 
aroused a new interest about its potential (Bishayee et al., 2011). The triterpenes, widely used in 
medicine in Asian countries, have a range of unique biological effects and have been studied for 
its anti-inflammatory, hepatoprotector, analgesic, antimicrobial, antimicotic, virostatic, 
immunomodulatory, tonic, anticancer, antiangiogenesis, analgesic, antipyretic, antioxidant, 
antiallergic, spasmolytic, anti-HIV and antimalarial effects (Dzubak et al., 2005; Kommera et al., 
2011; Yadav et al., 2010; Bishayee et al., 2011). Therefore, they can be considered a promising 
and expanding platform to biological active natural compounds whose potential is only partially 
explored by the pharmaceutical industry. 
 
4.1.1.1.   BETULINIC ACID 
Betulinic acid (BiA), 3β,hydroxy-lup-20(29)-en-
28-oic acid (Fig.7)  is part of the lupane group, a 
pentacyclic triterpene, and it can be found in several 
plants throughout the world like in Ziziphus spp., 
Amenone spp., Lycopodium spp., Syzygium spp., Betula 
spp., Tryphyllum spp., Ancistrocladus spp., Eucalyptus 
spp., Diopsyros spp., Paeonia spp. and Tetracera spp., Figure 7 – Chemical structure of betulinic acid. 
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being highly available in the white-barked birch tree (from the genus  Betula) (Cjowdhury et al., 
2002; Amin et al., 2009; Drag et al., 2009; Kommera et al., 2010a; Kim et al., 2011; Soica et 
al., 2011). Betulinic acid is the oxidized derivative of its precursor betulin, which was one of the 
first natural compounds to be isolated from plants more than two centuries ago (Cichewicz and 
Kouzi, 2004; Fulda and Kroemer, 2009). Depending on the extraction method, betulin 
comprehends over than 90% of the total isolated products and BiA around 1 to 5% (Drag et al., 
2009). 
Betulinic acid, a white crystalline solid, is a bioactive compound that possess a wide 
range of pharmacological effects like anti-inflammatory, antimicrobial, antiplasmodial, anti-HIV, 
anti-diabetic, cardiovascular, anti-atherosclerosis, anti-obesity, anti-proliferative, anti-angiogenic, 
cytotoxic, anticancer, antiparasitic, antimalarial, anti-viral, antioxidant, hepatoprotector, anti-
allergic and anti-tuberculosis effects as well as spasmogenic, anthelmintic and antinociceptive 
activities (Ryu et al., 1994; Cichewicz and Kouzi, 2004; Dzubak et al., 2005; Fulda and Kroemer, 
2009; Wu et al., 2010; Bishayee et al., 2011). It has been postulated that many of these effects 
may be due to its ability to modulate immune functions, being an important immunomodulator 
(Yi et al., 2010). 
The Native Americans used the bark of white birch tree (rich in BiA) as a potent folk 
medicine to treat skin diseases and as an anti-inflammatory (Fulda and Kroemer, 2009). The 
cytotoxic activity of BiA was first described in 1976 by Trumbull and collaborators, but it was only 
in 1995 that Pisha et al. published an important paper reporting the cytotoxic effects of BiA in a 
human melanoma cell line, causing an increasing interest in this compound. It was first thought 
that this compound was cytotoxic specifically to melanoma cell lines (Fulda, 2008; Fulda and 
Kroemer, 2009), but since then its anticancer activity has been reported against several other 
human cancers, including neuroblastoma, glioblastoma, colon, breast, liver, lungs and prostate 
carcinomas, among others (Cichewicz and Kouzi, 2004; Ehrardt et al., 2004; Fulda, 2008; Amin 
et al., 2009; Eichenmuller et al., 2009; Fulda and Kroemer, 2009;  Chintharlapalli et al., 2011). 
Many mechanisms of action have been published for explaining its anticancer effect. One 
of them is the ability of BiA to induce cell death by apoptosis (Drag et al., 2009; Eichenmuller et 
al., 2009; Santos et al., 2011), which is suggested to be mediated by the increase of 
mitochondrial membrane permeability, meaning through the intrinsic mitochondrial apoptosis 
pathway (Fulda et al., 1997; Dzubak et al., 2005; Fulda and Debatin, 2000; Zuco et al., 2001; 
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Ehrhardt et al., 2004; Liu et al., 2004; Jung et al., 2007; Fulda, 2008; Eichenmuller et al., 2009; 
Fulda and Kroemer, 2009; Wu et al., 2010; Bishayee et al., 2011; Kommera et al., 2011; 
Santos et al., 2011). Betulinic acid has also been proven to be a topoisomerase I and II inhibitor 
(Chowdhury et al., 2002; Wada and Tanaka, 2005) as well as being responsible by the 
downregulation of the transcription factors specificity protein 1 (Sp1), 3 (Sp3) and 4 (Sp4) (Drag 
et al., 2009; Chintharlapalli et al., 2011), which regulates the expression of a vast number of 
genes involved in many cellular functions from differentiation, proliferation and apoptosis 
(Deniaud et al., 2009). An interesting and clinically important fact is that BiA has a higher effect 
in an environment with pH lower than 6.8, which is the pH at which almost every tumours 
develops (Cichewicz and Kouzi, 2004; Dzubak et al., 2005). 
A very important characteristic that has been reported for this compound is its ability to 
trigger apoptosis in cancer cells resistant to drugs, suggesting that BiA may circumvent some 
forms of resistance in cancer patients that show resistance to chemotherapy (Fulda and Debatin, 
2000; Jung et al., 2007; Drag et al., 2009). Furthermore, despite its cytotoxicity against a variety 
of cancers, normal cells and tissues appear relatively resistant to BiA, taking up to 100 mg/kg in 
animal studies without showing great toxicity, which points to a very good therapeutic window 
(Zuco et al., 2002; Dzubak et al., 2005; Rzeski et al., 2006; Csuk et al., 2011). So, due to its low 
toxicity against normal tissues and cells, its remarkable anticancer activity and the fact that it can 
bypass drug resistance cancers, it can be expected that BiA will eventually be accepted as an 
adjuvant therapeutic in the treatment of cancer cells. However, BiA is a highly lipophilic molecule 
with limited water solubility (being limitedly soluble in organic alcohols and highly soluble in 
pyridine and acetic acid) which can lower its in vivo uptake. So, developing specialized 
formulations/carriers, such as liposomes, may help to augment its in vivo efficiency as an 
anticancer agent (Cichewicz and Kouzi, 2004;). 
Tough BiA is widely available in Nature, their sources may not be enough to a possible 
increase in the demand of this compounds. But, fortunately, the BiA’s precursor betulin is highly 
available in several species of plants with significant yields over 20%, and BiA is easily prepared 
from betulin in a simple two-step process (Chintharlapalli et al., 2011; Soica et al., 2011). Also, 
due to its outstanding characteristics, a number of new BiA derivatives are being synthetized 
(Kim et al., 2001; Liu et al., 2004; Rajendran, 2008; Kommera et al., 2010a; Nakagawa-Goto et 
al., 2010; Kommera et al., 2011; Santos et al., 2011). 
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4.1.1.2.   BETULONIC ACID 
Betulonic acid (BoA), 3-oxolup-20(29)-en-28-oic-acid (Fig.8), is also part of the lupane 
group and a pentacyclic triterpene, which can be found in Syzigium spp, Eucalyptus spp., 
Prunella spp., Ziziphus spp. and Betula spp. (Ryu et al., 1994; Symon et al., 2005; Domingues et 
al., 2010; Kommera et al., 2010a). Betulonic acid can also be obtained from betulinol or from 
betulin. The yield obtained from the extraction of BoA from betulinol is aroun 90%, whereas from 
betulin is only about 60% (Saxena et al., 2 006).  
Betulonic acid is a white crystalline solid, which, 
until the year 2000, was only focus of interest as a 
precursor of BiA (Melinokova et al., 2012). However, it 
was discovered that it was by itself a very valuable 
bioactive compound with great pharmacological 
activities such as anti-viral, anticancer, anti-
inflammatory, anti-malarial, anti-angiogenic, anti-HIV, 
cytotoxic, hepatoprotector, antioxidant, antimicrobial, 
and immunomodulatory (Pavlova et al., 2003; Sorokina 
et al., 2004; Sorokina et al., 2006; Vabilevsky et al., 2009; Melinokova et al., 2012; Semenov et 
al., 2012). In fact, it has been reported that in many of its effects, BoA is much more active and 
potent inhibitor than BiA, being immensely potent against several tumour cell lines (Symon et al., 
2005; Wada and Tanaka, 2005). Betulonic acid is also known for being a powerful 
topoisomerase II inhibitor (Ryu et al., 1994). 
As mentioned, BoA has a remarkable cytotoxic activity against cancers such as 
melanoma and prostate, neck and head, ovary/cervix, lung, colon, breast, thyroid and liver 
carcinomas (Saxena et al., 2006; Shintyapina et al., 2007; Kommera et al., 2010a). 
Due to its very low solubility in aqueous medium (being only soluble in organic solvents), 
it has not been yet possible to determine in all its extent BoA’s powerful activity (Saxena et al., 
2006). Also because of this, there is not yet literature that clarifies exactly the mechanisms of 
action of the anticancer activity of BoA, but it has been reported that it may up-regulate p53 
activity (Zhang et al., 2008). Also, it has been reported that BoA may be a powerful agent that 
Figure 8 – Chemical structure of betulonic 
acid. 
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improves cytostatic effects of drugs (as a bioregulator to decrease the organism resistance to 
toxic cytostatic effects) (Sorokina et al., 2004). 
As with BiA, BoA seems to be little toxic to normal fibroblast cells (Saxena et al., 2006). 
There has been also a number of BoA derivatives that are being synthesized (Vabilevsky et al., 
2009; Semenov et al., 2012). 
 
4.1.1.3.   URSOLIC ACID 
Ursolic acid (UA), 3β-hydroxy-urs-12-en-28-oic 
acid, (Fig. 9) is a natural pentacyclic triterpene 
carboxylic acid. It is widely present in several 
medicinal plants like sage, olive and rosemary as well 
as in some fruits, such as some berries and apples, 
and in eucalyptus (Liu, 1995; Domingues et al., 
2010). 
UA is also a bioactive compound and has numerous effects such as anti-inflammatory, 
anticancer and hepatoprotective effects (Liu, 1995; Xavier et al., 2009b; Xavier et al., 2013), as 
well as it is able to provide protection against oxidative damage in DNA (Ramos et al., 2008; 
Ramos et al., 2010). It also presents low toxicity to normal cells (Xavier et al., 2009b). It has 
been reported that UA’s anticancer effect is due to its capacity of modulating important signalling 
pathways, such as PI3K, inhibiting cell proliferation and inducing apoptosis (Liu, 1995 Xavier et 
al., 2009b; Xavier et al., 2012). 
 
4.1.1.4.   OLEANOLIC ACID 
Oleanolic acid (OA), 3β-hydroxy-olea-12-en-28-oic acid, (Fig.10) is a natural occurring 
triterpenoids that is found in Phytolacca spp., Syzygium spp., Eucalyptus spp., in garlic and other 
medicinal plants (Liu, 1995; Domingues et al., 2010). 
Figure 9– Chemical structure of ursolic acid. 
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OA is a bioactive compound and possesses 
interesting effects such as hepatoprotector, 
anticancer, anti-HIV and antiviral activities, being little 
toxic to normal cells and tissues (Liu, 1995). It has 
been reported that, besides being less potent in 
inducing cell death than UA, it may be used in cancer 
treatment in specific physiological conditions, such as 
under metabolic stress (Duarte, 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – Chemical structure of oleanolic. 
id 
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OBJECTIVES OF THE WORK 
Portugal is one of the leading countries in the production of eucalyptus for the pulp and 
paper industry. However, this sector is responsible for the production of tons of bark residues 
that does not have a valuable use. The present work intends to give a contribution to the 
exploitation of this byproduct of the pulp and paper industry as possible source of high-added-
value bioactive compounds, a study that is under the scope of the European project AFORE (FP7: 
CP-IP 228589-2 AFORE) that intends to develop novel applications for forest residues. 
Therefore, the objective of this work was to study the potential anticancer effect of the 
triterpenic fraction of extracts obtained from the bark of E. nitens in colorectal cancer cells. An 
enriched triterpenic fraction (F2) in BiA and BoA was also tested and, in addition, these two 
isolated compounds. 
For that, the anticancer potential of the triterpenic extracts/compounds was studied by 
the MTT assay, the anchorage-dependent colony forming assay and by the cell migration assay 
(wound healing). Induction of cell death and apoptosis was studied by the PI staining and the 
presence of nuclear condensation, respectively. In addition, effects on cell cycle were studied by 
flow cytometry. Finally, the involvement of several signalling pathways, related with proliferation 
and death, in the effects of the triterpenic extracts/compounds were analysed by western blot. 
With this work we intend not only to establish the importance of triterpenoids compounds 
as anticancer agents, but also to test an important source of these compounds that are being 
disregarded as residues from crops used in the pulp and paper industry. 
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1. CHEMICALS 
Propidium iodide (PI), quercetin, RNAse A, 3-(4,5-Dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide (MTT), RPMI 1640, antibiotic/antimicotic solution, bovine serum 
albumin (BSA), N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) was bought from Biochrom 
AG (Berlin, Germany). All the other compounds were of analytical grade. 
 
2. EUCALYPTUS NITENS  EXTRACTS AND TRITERPENOIDS 
Betulinic acid and betulonic acid were purchased from Molekula Ltd (Gillingham, Dorset, 
United Kingdom) and Chemos GmbH (Regenstauf, Germany), respectively. Eucalyptus nitens 
crude extract (E. nitens CE) and the triterpenic enriched fraction 2 (E. nitens F2) were kindly 
provided by Professor Armando Silvestre from the Department of Chemistry, University of Aveiro. 
The extracts were prepared by Domingues et al. through extraction of E. nitens bark with 
dichlorometane as previously described (Domingues et al., 2011). The CE and F2 extracts of E. 
nitens were then analysed by GC-MS and the main chemical composition present in Table 1 
(Domingues et al., 2012, unpublished data). Extracts and isolated compounds were dissolved in 
dimethyl sulfoxide (DMSO) in stock solutions, in order that DMSO concentration in cell culture 
was no higher than 0.5% (v/v). Controls received vehicle only. 
 
3. ANTIBODIES 
The primary antibodies were purchased from the following sources: anti-phospho-ERK, 
anti-PARP-1, anti-phospho-JNK, anti-Bcl-2 and anti-p53 from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA, USA); anti-caspase 9, anti-phospho-p38 MAPK (Thr180/Tyr182), anti-phospho-
AMPKα (Thr172) and anti-phospho-Akt (Ser473) from Cell Signalling (Danvers, MA, USA); anti-
caspase 3 from Calbiochem (San Diego, CA, USA); and anti-β-actin from Sigma-Aldrich. 
Secondary antibodies anti-rabbit and anti-mouse were purchased from Santa Cruz Biotechnology. 
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Table 1 – Chemical composition (based on % of weight from the total extract weight) of the E. nitens crude extract 
and of the triterpenic enriched fraction 2 (Domingues et al., 2012, unpublished data). 
Compounds Crude extract (%) Fraction 2 (%) 
Fatty acids 1.2 4.2 
Long chain aliphatic alcohols 0.9 0.2 
Sterols 1.2 0.0 
Triterpenoids 70.7 93.3 
β-amirin 0.3 0.0 
Lupeol 0.3 0.0 
Betulonic acid 7.0 24.2 
Oleanolic acid 20.8 15.5 
Betulinic acid 19.0 32.5 
Ursolic acid 10.2 15.5 
3-acetyloleanolic acid 3.2 0.0 
3-acetylursolic acid 1.8 0.6 
Unidentified triterpenoids 8.1 4.9 
Other compounds 1.9 0.0 
Unidentified compounds 24.1 2.3 
 
4. CELL CULTURE 
HCT116 cells (human colorectal carcinoma cell line) were kindly provided by Professor 
Raquel Seruca from IPATIMUP, Porto. The cell line was maintained in culture in 25 cm2 
polystyrene flasks (TPP, Switzerland) with RPMI 1640 medium, containing 6% FBS, 1% antibiotic–
antimicotic solution, 0.1 mM sodium pyruvate, 10 mM HEPES and 2 g/L sodium bicarbonate 
under an atmosphere of 5% CO2 and 95% air at 37°C. 
 
5. MTT REDUCTION ASSAY 
MTT reduction assay was performed to evaluate the potential of the tested 
compounds/extracts to decrease the number of viable cells as previously described (Lima et al., 
2011). Briefly, HCT116 cells were plated in 24-multiwell culture plates at 8x104 cells per ml and 
allowed to grow for two day. Cells were incubated with test compounds/extracts at different 
concentrations and for different time periods. One hour before the end of incubation, 50µL of 
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MTT (final concentration of 0.5mg/ml) was added to each well. When the incubation time ended, 
the medium was removed and discarded, and the formazan crystals (formed by the cell’s 
capacity to reduce MTT) were dissolved with a 50:50 (v/v) DMSO:ethanol solution. The 
absorbance was measured at 570nm, with background subtraction at 690nm. The results were 
expressed as percentage relative to the control. The concentration of each test compound/extract 
that decreases the number of viable cells to half (IC50) was calculated using mathematical 
modelling with the program GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). 
                                                                                                                                                                                                                                                                                                                                                                                                                     
6. ANCHORAGE-DEPENDENT COLONY FORMING  
The anticancer potential of tested compounds/extracts was also tested by their ability to 
inhibit the formation of cell colonies. HCT116 cells were plated in 6-multiwell culture plates at 
500 cells per ml for two days for cell attachment. Cells were then incubated with different 
concentration of test compounds/extracts dissolved in new culture medium for six days (without 
changing the medium). After this incubation time, medium was removed from the wells, washed 
with PBS and cells fixed with ice cold absolute ethanol for 15 minutes. Then, cells were stained 
with Giemsa working solution (0.4% w/v) for 5 minutes and the wells washed with tap water. The 
plate wells were photographed and colony forming ability estimated by quantifying colony area 
intensity using appropriate image analysis system (Adobe Photoshop CS3 Adobe Systems 
Incorporated, San Jose, CA, USA). 
 
7. CELL DEATH ANALYSIS BY PROPIDIUM IODIDE (PI) STAINING  
PI staining was performed to evaluate cell death induced by the tested 
compounds/extracts. This DNA fluorophore is impermeable to live cells, but will stain strongly the 
DNA of dying and death cells due to their compromised or permeabilized plasma membranes 
(Rieger et al., 2011) The HCT116 cells were plated in 6-multiwell culture plates at 8x104 cells per 
ml, for two days for cell attachment and growth, before incubating them with test 
compounds/extracts dissolved in new culture medium. After treatment with different 
concentrations and incubation times, cells were collected (both floating and attached cells) 
washed with cold PBS containing 6% (v/v) FBS, and incubated with PI added to a final 
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concentration of 0.25mg/ml for 10 minutes. The percentage of cells positive for PI (death cells) 
was quantified by flow cytometry using a Coulter Epics XL Flow Cytometer (Beckman Coulter Inc., 
Miami, FL, USA) counting at least 40,000 cells per sample. An example of quantification of cell 
death by flow cytometry with PI staining is given in the Figure 11.  
 
 
 
 
 
 
 
 
 
 
 
8. NUCLEAR CONDENSATION  
Nuclear condensation was performed in order to estimate cell death by apoptosis. The 
HCT116 cells were plated in 12-multiwell culture plates at 8x104 cells per ml, for two days before 
incubating them with different concentrations of test compounds/extracts dissolved in new 
culture medium. After 48h of treatment, cells were collected (both floating and attached cells) 
and washed with PBS. Cells were then fixed resuspending them in paraformaldehyde (PFA) 4% 
(w/v) in PBS for 20 minutes, and washed again with PBS. Cells were attached into a polylysine 
treated slide using a Shandon Cytospin 4 (Thermo Scientific, Waltham, MA, USA), and incubated 
with Hoechst (final concentration of 5µg/ml) for DNA staining. Nuclear morphology was 
visualized on a fluorescent microscope and photos taken from different fields of each sample. 
The percentage of apoptotic cells were calculated from the ratio between cells with nuclear 
Figure 11 – Representative images of flow cytometry for analysing cell death by PI staining, of 
a control sample (A) and a treatment condition with induction of cell death (B). Represented in 
the plots are life cells – cells at gate D with red autofluorescence (PI negative), and dead cells – 
cells at gate E with PI red fluorescence (PI positive). The percentage of cell death is given by the 
formula   𝐄 
𝐃+𝐄
× 𝟏𝟏𝟏. 
PI Staining PI Staining 
A B 
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condensation typical of apoptosis and the total number of cells, from a count higher than 500 
cells per sample. 
 
9. CELL CYCLE ANALYSIS 
The analysis of cell cycle was done by flow cytometry using PI for staining DNA of 
permeabilized cells. For that, HCT116 cells were plated in 6-multiwell culture plates at 8x104 
cells per ml for two days for cell attachment and growth, before incubating them with the test 
compounds/extracts dissolved in new culture medium. After treatment for 48h with different 
concentrations of compounds/extracts, cells were collected (both floating and attached cells) and 
washed with cold PBS. Then, cells were fixed and permeabilized in ice cold ethanol 70% (v/v) for 
15 minutes and washed again with PBS. Finally, cells were incubated with staining solution (50 
µg/ml PI and 20 µg/ml RNase A in PBS) at 37ºC for 15 minutes. Analysis of cell cycle 
progression by flow cytometry was done using a Coulter Epics XL Flow Cytometer (Beckman 
Coulter Inc.) counting at least 40,000 single cells per sample. Phases of cell cycle were fitted 
using the mathematical Watson Pragmatic model with the FlowJo Analysis Software (Tree Star, 
Inc., Ashland, OR, USA). 
 
10. MIGRATION ASSAY (WOUND HEALING) 
Migration assay was performed to evaluate the effect of tested compounds/extracts to 
affect the extent of wound closure. For that, HCT116 cells were plated in 12-multiwell culture 
plates at 2.5x105 cells per ml, and allowed to grow for two days until cell confluence was 
reached. Cell layer was then wounded in an x shape with an 100 µl tip, and a photo of the 
wound site was taken. Cells were incubated with the test compounds/extracts for 24h and a new 
photo in the central wound site taken. The extend of wound closure was given as the percentage 
of covered area after 24h in relation to the initial uncovered area, using the following formula: 
Extent of wound closure = �Initial uncovered area-Final uncovered area�Initial uncovered area ×100  
and used to estimate the cells’ migration ability. 
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11. WESTERN BLOTTING  
To measure the expression of different proteins involved in cell signalling and apoptosis 
western blot was used using total cell homogenates. HCT116 cells were plated in 6-multiwell 
culture plates at 8x104 cells per ml for two days for cell attachment and growth. Cells were 
treated with different concentrations of tested compounds/extracts for 24h or 48h and a total  
cell homogenate obtained incubating cells for 15 minutes at 4ºC with ice cold RIPA buffer (1% 
NP-40 in 150mM NaCl, 50mM Tris-HCl (pH 8), 2mM EDTA) containing 1mM PMSF, 
phosphatase inhibitors (20mM NaF, 20mM Na2V3O4) and protease inhibitor cocktail (Roche, 
Mannheim, Germany). Protein concentration was quantified by Bio-Rad DC protein assay (Bio-
Rad Laboratories, Hercules, CA, USA) and BSA used as protein standard. For Western Blot, 20 
µg of protein was resolved in SDS-polyacrilamide gel and then electroblotted to a polyvinylidene 
difluoride membrane (Millipore, Billerica, MA, USA). Membranes were blocked in TPBS (PBS with 
0.05% of Tween-20) containing 5% (w/v) of non-fat dry milk, washed in TPBS and incubated with 
primary antibody overnight. After washing, membranes were incubated with the secondary 
antibody for 1h, and membranes washed again. The immunoreactive bands were detected using 
the Immobilon solutions (Millipore) under a chemiluminescence detection system, the Chemidoc 
XRS (Bio-Rad Laboratories). Band area intensity was quantified using the Quantity One software 
from Bio-Rad. β-actin was used as loading control. 
 
12. STATISTICS 
Data expressed as the mean ± SEM of at least 3 independent experiments. Statistical 
significances among data groups were analysed by one-way ANOVA followed by the Dunnett’s 
multiple comparison test, or by the Student’s t-test, as appropriate, using GraphPad Prism 5.0 
software (San Diego, CA, USA). Differences between groups were considered statistically 
significant when P≤0.05. 
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The pulp and paper industries are one of the most important industries in Portugal 
contributing positively to the country’s export (Pereira et al., 2005; Domingues et al., 2010; 
Domingues et al., 2011b; Moura et al., 2012). Eucalyptus wood is the main source of fibbers for 
the production of paper. However, it generates large amounts of residues, mainly bark, which 
can be a source of valuable compounds of otherwise burned or discarded material (Doningues et 
al., 2011). Therefore, the exploitation of this byproduct for the production of interesting added-
value new products is being viewed by the pulp and paper industry as a way to increase their 
revenue and to implement the biorefinery concept in their production chain (Domingues et al., 
2011a; Mota et al., 2012). Previously, it was reported that lipophilic extracts from the bark of 
Eucalyptus species can be an important source of high-value triterpenic compounds in view of 
their high content and attributed bioactive properties (Domingues et al., 2011a). 
In the present work, the potential anticancer effect of lipophilic extracts enriched in 
triterpenic acids obtained from the bark of E. nitens was studied in the colorectal HCT116 cancer 
cells. Although E. nitens is not the main species of eucalyptus in Portugal, it possess high content 
of triterpenic acids like the most abundant species E. globulus, but contrarily to this one, where 
ursane acids dominates, it is the richest in oleanane and lupane acids (Domingues et al., 
2011a). 
For this work, two extracts of E. nitens were used (see Table 1, in Materials section): a 
lipophilic crude extract (CE) with about 70% (w/w) of triterpenoids, where the main ones are 
oleanolic acid (20.8%) followed by betulinic acid (19%), ursolic acid (10.2%) and betulonic acid 
(7%); and, a fraction (F2) of the CE more enriched in triterpenoids (about 93% of total weight), 
specially in lupane acids, since the main ones are betulinic acid (32.5%) followed by betulonic 
acid (24.2%), ursolic acid (15.5%) and oleanolic acid (15.5%). In addition, the above lupane acids 
were also tested alone for comparison. 
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1. TRITERPENIC ACIDS-ENRICHED EXTRACTS FROM E. NITENS POSSESS ANTICANCER ACTIVITY 
AGAINST HCT116 CELLS 
In order to study the anticancer potential of the two E. nitens extracts, HCT116 cells 
were incubated for 48h with different concentrations of CE or F2 extracts, and cell viability 
evaluated by the MTT assay (Fig. 12). As shown in Fig. 12A & 12C, both extracts presented high 
anticancer activity, decreasing significantly the number of viable cells in a concentration 
dependent manner. Based on these results, their IC50 (concentration of extract necessary to 
decrease by half the number of viable cells as compared with negative control) were calculated 
and presented as an example for the E. nitens CE in Fig. 13A. The results showed that the E. 
nitens F2 extract was more active than the E. nitens CE extract, with IC50s of 1.3 µg/ml and 2.2 
µg/ml, respectively. 
Considering the high content of these extracts in triterpenoids, especially in betulinic, 
betulonic, oleanolic and ursolic acids, the main compounds were also tested alone. In a previous 
work of our group (Duarte, 2012), the anticancer potential of both UA and OA were evaluated in 
HCT116 cells using the same culture conditions than here. Whereas for UA a good anticancer 
activity was obtained with an IC50 of 8 µM, for OA no significant decrease of cell viability was 
observed until the highest concentration tested (50 µM), meaning that the IC50 is much over this 
value. In the present work, the remaining two main triterpenoids of the E. nitens extracts, BiA and 
BoA, were tested. Both compounds exhibit a high capability to decrease the number of viable 
cells, also in a concentration-dependent manner (Fig. 12D and E). Interestingly, BoA presents a 4 
times lower IC50 concentration than BiA, with 0.8 µM and 3.9 µM, respectively, and a 10 times 
lower than UA. 
Converting the IC50 of the isolated compounds from µM to µg/ml, and taking into 
account the percentage of each compound in both extracts, the concentration range of the 
isolated compounds are in the same order of magnitude than that of the extracts. However, a 
compound alone does not explain the total extract activity, which suggests that all the three main 
active triterpenoids BoA, BiA and UA contribute to the extracts’ activity. Interestingly, taking into 
account only these three triterpenoids, E. nitens F2 extract has about two times more of their 
quantity than E. nitens CE (see Table 1, in Materials section), and the IC50 of the former is about 
half of the latter. This observation corroborates that the activity of the E. nitens extracts dependes 
mainly from the three active triterpenoids (OA is non-active until 50 µM). 
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Fig. 12 – Effects of E. nitens CE (B) and F2 extracts (C), as well as the isolated compounds betulinic acid (D) and 
betulonic acid (E) in cell viability of HCT116 cells after 48h of incubation, as measured by the MTT assay. In (A) is 
presented, as an example, data of (B) with a sigmoid mathematical modelling with the program GraphPad Prism for 
calculation of the IC50 value. The same metod was used to calculate the IC50 given in C, D and E. Values are mean ± 
SEM of at least three independent experiments. * P≤0.05, ** P≤0.01, *** P≤0.001, when compared with respective 
control, analysed by one-away ANOVA with Dunnett’s multiple comparison test.  
A 
E D 
C B 
IC50 = 1.3 µg/ml IC50 = 2.2 
/ l 
IC50 = 3.9 µM IC50 = 0.8 µM 
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The morphologic changes observed in HCT116 cells after being incubated for 48h with 
eucalyptus extracts (Fig. 13A) or isolated lupane acids (Fig. 13B), also agrees to their potent 
anticancer activity. Along with the increasing concentration of the extract/compound, the number 
of adherent (live) cells decreased and the floating (dead) increased. The anticancer activity of 
eucalyptus extracts has been poorly investigated. Recently, polyphenolic-rich extracts from E. 
globulus bark demonstrated some capacity to reduce human breast cancer cell proliferation 
(Mota et al., 2012). In addition, Islam et al. (2012) showed the anti-tumour activity of a lipophilic 
extract of E. camaldulensis against Ehrlich ascites carcinoma celsl in mice. In the present work, it 
was demonstrated a high anticancer potential of triterpenic acids-rich extracts from E. nitens bark 
in colorectal cancer cell, with IC50 of about 2 µg/ml. 
Fig. 13 – Representative images of the effect of different concentrations of E. nitens crude extract (CE) and E. 
nitens fraction 2 (F2) extract (A), and test compounds betulinic acid (BiA) and betulonic acid (BoA) (B) on the 
morphology of HCT116 cells  after 48h incubation. Photos were taken with an objective of 10 times magnification 
in an inverted microscope (Olympus IX71 – Lisboa, Portugal) with phase contrast. 
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The anticancer potential of their main triterpenoids are, however, described in the 
literature. Many studies (Cichewicz and Kouzi, 2004; Ehrardt et al., 2004; Symon et al., 2005; 
Wada and Tanaka, 2005; Fulda, 2008; Amin et al., 2009; Eichenmuller et al., 2009; Fulda and 
Kroemer, 2009;  Chintharlapalli et al., 2011), including our owns (Ramos et al., 2008; Xavier et 
al., 2009b; Ramos et al., 2010; Xavier et al., 2012), demonstrated the anticancer activity of 
these triterpenoids against several types of tumours cells. Many mechanisms of action, mainly 
for UA (Liu, 1995 Xavier et al., 2009b; Xavier et al., 2012) and BiA (Deniaud et al., 2009), were 
also depicted. Considering that OA is non-active in HCT116 cells and that the lupane acids were 
more active than UA, along with the E. nitens extracts, the work was proceeded with BiA and 
BoA. 
The observed decrease in the number of viable cells induced either by the extracts or by 
the isolated compounds could have been a result of inhibition of cell proliferation and/or 
induction of cell death. As to better clarify that, some concentrations of extracts and compounds 
were chosen and their effect on cell viability along with different times of incubation (6, 24, 48 
and 72h) was measured by MTT reduction assay (Fig. 14A, C, E and G). Furthermore, cell death 
was followed by flow cytometry by measuring the ability of live cells to exclude PI after different 
times of incubation (24, 48 and 72h) (Fig. 14B, D, F and H). 
As shown in Fig. 14A, cells incubated with 1 or 2.5 µg/ml of E. nitens CE accompanied 
the growth of control cells until 24h of incubation, but decreased significantly after 48h. On other 
hand, cells incubated with 10 µg/ml of CE did not grow in the first 24h but did not induce cell 
death (Fig.13B). With the PI staining assay, cell death was only observed after 48h of incubation 
and in a concentration-dependent manner (Fig. 14B). At 72h, the same results were obtained, 
but with a higher magnitude of cell death. The pattern of results of E. nitens F2 (Fig. 14C and D) 
was similar to the ones of CE. However, the magnitude of effects was higher at lower 
concentrations, which, once more, shows that the F2 has higher anticancer activity when 
compared to the CE. Regarding the isolated compounds, cell death was already visible at 24h of 
incubation with the higher tested concentration of each compound, 15 µM for BiA and 50 µM for 
BoA, being of notice that even tough BiA’s concentration is significantly lower than BoA’s, it 
shows more cell death (Fig. 14F and H). This result seems contradictory to the IC50 value 
calculated for BiA when compared with BoA. However, at 48h of incubation, BoA at lower doses 
induces higher cell death as compared with BiA, which agrees with the MTT assays (Fig. 14E, F,  
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A 
H G 
F E 
D C 
B 
Fig. 14 – Effect of E. nitens crude extract (CE), E. nitens fraction 2 (F2), betulinic acid and betulonic acid at different 
concentrations in cell viability of HCT116 cells along the time. (A, C, E and G) Number of viable cells measured by the 
MTT assay. (B, D, F and H) Cell death evaluated by the PI staining as measured by flow cytometry. Values are mean ± 
SEM of at least three independent experiments. * P≤0.05, ** P≤0.01, *** P≤0.001, when compared with respective 
control, analysed by the Student’s t-test. 
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G and H).  All of these results seem to indicate a contribution of both inhibition of cell 
proliferation and induction of cell death in the observed reduction of viable cells by the extracts 
and the compounds. 
In order to confirm the anticancer potential of the triterpenic acid-enriched E. nitens 
extracts and its main compounds, an anchorage-dependent colony formation assay and cell 
migration assay was performed. As shown in Figure 15A, the two tested extracts and compounds 
exhibited a marked inhibition of colony formation and growth in a concentration-dependent 
manner. The observed effects resulted mainly from inhibition of cancer cell colonies growth and 
colony size – Fig. 15B – since concentrations of extracts/compounds that induced cell death, in 
the conditions used in this assay (concentrations higher than that present in Fig. 15), were 
discarded. In accordance with the results of the cell viability assay, E. nitens F2 extract was 
shown to be more potent than the CE, having the concentrations of the first (2.5 and 5 µg/ml) 
achieved the same results of the latter at 5 and 10 µg/ml (Fig.15). However, for the triterpenoids 
BiA and BoA a similar inhibition of colonies growth were obtained for the same concentrations. 
As expected, the positive control – starved cell (grown in medium with 0.6% (v/v) FBS) – resulted 
in marked colonies growth inhibition. 
For the migration assay, the capacity of cells to wound healing/closure were evaluated in 
the presence of different concentrations of extracts/compounds for 24 hours. As a positive 
control, cells were incubated in starvation medium (medium with 0.6% (v/v) FBS), and 
representative images of this and control cells are present in Figure 15B. In the migration assay, 
the wounds were made in a confluent cell layer, in order that the wound closure would be 
dependent on cell migration and not on cell proliferation. When cells reach confluence, they 
acquire a quiescent state, where cell cycle pauses at G0 state (Coller et al., 2006). 
Figure 16A shows that the lower concentrations of either the extracts or the compounds 
do not have any effect on the cell migration ability, being their values very similar to those of the 
control. However, with a higher concentration we did obtain migration inhibition in cells treated 
with the extracts and the compounds. Rzeski and collaborators (2006) had previously reported 
that cultures treated with BiA had a significant lower number of cell migrating to the wounded 
area. Taking into account the two E. nitens extracts, it was observed again that half the 
concentration used for the CE obtain the same result for F2. The same also happens with the 
isolated compounds, where 5 µM of BoA has the overall same result of 10 µM of BiA (Fig. 16A),  
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Fig. 15 – Effect of E. nitens crude extract (CE), E. nitens fraction 2 (F2), betulinic acid and betulonic acid in the 
ability to inhibit colony forming in HCT116 cells. Cells were incubated with test compounds/extracts (controls 
received vehicle only – DMSO; starved cells received 0.6% (v/v) FBS-containing medium) for six days before 
being fixed and stained with Giemsa. A) Values are expressed as the mean area intensity of colonies and are 
mean ± SEM of the mean area intensity of colonies of at least three independent experiments. * P≤0.05, ** 
P≤0.01, *** P≤0.001, when compared with respective control, analysed by the Student’s t-test. B) 
Representative images of the anchorage-dependent colonies formation in HCT116 cells under the effect of tested 
compounds/extracts for six days. 
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demonstrating, once more, that BoA is a more potent compound than BiA. The effect of higher 
concentrations of extracts/compounds than that shown in Figure 16 was not shown, since 
inhibition of wound closure did not result from inhibition of cell migration, but noticeably from 
induction of cell death, in the conditions used in this assay. 
A 
Control 
Control + 
(Starved cells) 
24 h 0h 
Control 
Control + 
(Starved cells) 
B 
Fig. 16 – Effect of E. nitens crude extract (CE), E. nitens fraction 2 (F2), betulinic acid and betulonic acid in the ability of 
HCT116 cells to migrate. Cells were incubated with test compounds/extracts (controls received vehicle only – DMSO; 
starved cells received 0.6% (v/v) FBS medium) for 24 hours. A) Values are given as mean ± SEM of the percentage of 
covered area after 24h in relation to the initial uncovered area, of at least three independent experiments. * P≤0.05, *** 
P≤0.001, when compared with respective control, analysed by the Student’s t-test. B) Representative images of the 
wound before (0h) and after 24 hours of incubation for the negative control (complete medium with vehicle) and the 
positive control (starved cells) (bar – 500 µm). 
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All the present results show that BoA is the most active anticancer compound for 
HCT116 cells between the tested triterpenoids. Eucalyptus nitens bark can be an interesting 
source of extracts rich in bioactive triterpenoids, namely BoA, BiA and UA, with potent anticancer 
activity against HCT116 cells. 
 
2. APOPTOSIS CONTRIBUTES TO THE CELL DEATH INDUCED BY E. NITENS EXTRACTS AND THEIR 
MAIN LUPANE ACIDS IN HCT116 CELLS 
Considering the cell death induced by the tested extracts and compounds, we wondered 
whether it was apoptosis dependent. During apoptosis, DNA is fragmented and condensed in 
order to be included in the apoptotic bodies (Elmore, 2007). Therefore the ability of the E. nitens 
extracts and tested isolated compounds to induce nuclear condensation in HCT116 cells after 
48h of incubation, as a marker of cell death by apoptosis, were studied. As shown in Figure 16, 
apoptosis occurs in cells treated with either the extracts or the compounds, but only at the higher 
tested concentrations. Among the E. nitens extracts, F2 seems to be more potent inducing 
apoptosis than CE, since the first has about five times more apoptosis at 10 µg/ml than control 
cells, whereas the latter has no effect. Interestingly, BiA, which has a higher IC50 than BoA at 
48h, has a higher ability to induce cell death by apoptosis at lower doses (Fig.17A). Some 
intermediate concentrations of the tested extracts or compounds that already induced cell death 
as assessed by the PI staining (Fig.14), did not, however, induce apoptosis. So, nuclear 
condensation assay was also performed after 72h of incubation with these concentrations of 
extracts/compounds that induce cell death as observed with PI staining, but no induction of 
apoptosis was observed (data not shown).  
These results indicate that our tested extracts and compounds are able to induce cell 
death by apoptosis only at high concentrations. At lower or intermediate concentrations cell death 
occurs, but is not as a result of apoptosis but through some kind of non-apoptotic type of cell 
death.  
Whilst there is no scientific data as how E. nitens extracts or BoA induces apoptosis in 
cancer cells, it has been reported that BiA induces apoptosis in cancer cells through activation of 
the intrinsic mitochondrial pathway (Fulda and Debatin, 2000). Therefore, the levels of several 
proteins related with apoptosis were evaluated by western blot after treating HCT116 cells with  
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Fig. 17 – Effect of E. nitens crude extract (CE), E. nitens fraction 2 (F2) extract, betulinic acid and betulonic acid in the 
in the presence of nuclear condensation in HCT116 cells for 48h, as a marker of apoptosis. A) Values are mean ± 
SEM of at least three independent experiments. * P≤0.05, ** P≤0.01, *** P≤0.001, when compared with respective 
control, analysed by the Student’s t-test. B) Representative images of the induction of apoptosis in HCT116 cells by the 
tested compounds/extracts after 48h incubation; arrows indicate apoptotic cells with condensed and fragmented 
nuclear chromatin (bar – 50 µm). 
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either an eucalyptus extract or a tested triterpenoids compound. HCT116 cells possess a wild-
type p53 (Kim et al., 2012), and therefore are prone to p53-dependent apoptosis. Thus, the 
natural flavonoid quercetin was used in this work as a positive control, since it was previously 
shown to induce p53 and caspases-dependent apoptosis in colorectal cancer cells (Xavier et al., 
2011). 
During apoptosis, caspases are the execution proteins responsible for the cell death 
program. Their sequential cleavage results in their activation that in turn will end in the cleavage 
of critical cellular substrates, including poly(ADP.ribose) polymerase-1 (PARP1) (Chaitanya et al., 
2010). In the intrinsic mitochondrial pathway of apoptosis, a suppression in the anti-apoptotic 
protein Bcl-2 and increase of the pro-apoptotic Bax protein result in the imbalance of the Bcl-
2/Bax ratio, with the consequent permeabilization of the mitochondrial membrane, the release of 
cytochrome c and apoptosome assembly that leads to caspase 9-mediated caspase 3 activation 
(Fulda et al., 1997; Fulda, 2008). The cleavage of caspases and PARP1 (inactivating it) are 
considered good markers of apoptosis (Chaitanya et al., 2010). 
As observed in Figure 18B, all the extracts and compounds at the higher concentrations 
tested induced the cleavage of caspase 9, the decrease of procaspase 3 levels (an indirect 
indication of cleavage of caspase 3) and the cleavage of PARP1 after 48h of incubation. These 
results corroborate that apoptosis are triggered by both eucalyptus extracts and by their main 
lupane triterpenoids acids, but that did not occur at intermediate concentrations where cell death 
already take place. 
 Among the triterpenoids, the western blot results also showed that BiA is more active 
than BoA, since cleavage of PARP1 were present at 10 µM and 15 µM in BiA but not in BoA 
(Figure  18), regardless the lower IC50 for the later. Interestingly, BiA at 15 µM already induced 
PARP1 cleavage in HCT116 cells after 24h of incubation. It is important to note that, as seen on 
Figure 14F, this was also the concentration that, after 24h of incubation, has a significant 
percentage of cell death assessed by PI staining, unlike BoA and the two extracts that did not 
present significant death at time. These results confirm the superior ability of BiA to induce cell 
death by apoptosis, as compared to BoA. Previous results in literature also reported the ability of 
BiA to induce apoptosis in leukaemia and neuroblastoma cancer cells accompanied by cleavage 
of caspase 3 and PARP1 (Fulda and Debatin, 2000; Wu et al., 2010). The levels of Bcl-2 
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decrease in a concentration-dependent manner, especially for E. nitens CE, BiA and BoA, even at 
concentrations that apoptosis was not present (Figure 18B). 
Different types of stresses, including DNA damage, can trigger apoptosis, and the p53 
tumour suppressor is an important regulator in the process (Chari et al., 2009). Therefore, the 
levels of p53 were also measured by western blot and shown in Figure 18. As expected, the 
positive control quercetin (50 µM) induced the levels of p53 accompanied by cell death by 
apoptosis, as shown by the cleavage of caspase 9 and PARP1 as well as the decrease in the 
levels of procaspase 3 and Bcl-2 (Figure 18), and the induction of nuclear condensation (data not 
shown). 
As shown in Figure 18A, contrarily to quercetin, both eucalyptus extracts, BiA and BoA, 
decrease the expression of p53 protein in a concentration-dependent manner after 24h of 
incubation. After 48h of incubation, the decrease of p53 levels was even stronger, especially for 
eucalyptus extracts and BoA at concentrations that cell death occurs independent of apoptosis 
(Figure 18B). Although p53 can interact with members of the Bcl-2 family to induce the 
mitochondrial pathway of apoptosis (Vaseva and Moll, 2009), these results may indicate that 
apoptosis induced by these extracts/compounds is not dependent in p53. However, that needs 
to be elucidated in further experiments. Interestingly, in a previous result in our laboratory, UA 
was also shown to decrease the levels of p53 in colorectal cancer cells (Xavier et al., 2013), 
which may indicate that triterpenoids in general may be involved in reduction of p53 levels. The 
p53 suppression may be explained either by the interruption in its synthesis or by a fastest 
HDM2 activation that leads to the proteosome-related degradation of p53 (Zhang et al., 2010). 
Although this needs to be clarified in following experiments, it was reported that, in fact, BiA is an 
inducer of proteosome to increase protein degradation (Huang et al., 2007). Since these extracts 
and triterpenoids induce apoptosis apparently independent of p53, it would also be interesting to 
test in further experiments whether these extracts/compounds would be able to induce this type 
of cell death in apoptotic-resistant cancer cell lines with p53 mutations. 
Overall, these results indicate that apoptosis mediated by the mitochondrial-caspase 9-
caspase 3 axis contributes to the cell death induced by the eucalyptus extracts and their isolated 
compounds BiA and BoA in HCT116 cells, mainly at higher concentrations. At intermediate 
concentrations, a non-apoptotic type of cell death occurs together with loss of p53. 
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Fig. 18 – Effect of E. nitens crude extract (CE; at 10 and 25 µg/ml), E. nitens fraction 2 (F2) extract (at 5 and 25 
µg/ml), betulinic acid (BiA; at 5, 10 and 15 µM)) and betulonic acid (BoA; at 2.5, 15 and 25 µM)) on the levels of: 
A) phospho-JNK, phospho-AMPK, p53 and PARP1 after 24h of incubation; B) p53, Bcl-2, caspase 9, caspase 3 
and PARP1 after 48h of incubation, using western blot. β-Actin was used as loading control. Images are 
representative of at least three independent experiments. 
A 
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3. EUCALYPTUS NITENS EXTRACTS AND THEIR MAIN LUPANE ACIDS INDUCE JNK AND AMPK 
SIGNALLING IN HCT116 CELLS 
Different signalling pathways play a fundamental role in cancer development. In 
pathways related with promotion of cell proliferation and inhibition of apoptosis, usually a kinase 
(proto-oncogene) is mutated resulting in the constitutive activation of the signalling pathway 
without external mitogenic signals (Orton et al., 2005). The HCT116 cell line has an activation 
mutation in KRAS, which usually results in the activation of both MAPK/ERK and PI3K/Akt 
pathways. 
In this work, the activity of these pathways was assessed by measuring the 
phosphorylation status of their end kinases – ERK and Akt, respectively – as previously described 
(Xavier et al., 2009b). As expected for a KRAS-mutated cell line, phosphor-ERK levels were high 
even after 24h of incubation (time after medium change). However, both the extracts and 
isolated compounds BiA and BoA did not change (either induction or inhibition) significantly the 
phosphorylation levels (data not shown). In a previous study, Xavier et al. (2009b) also showed 
that the MAPK/ERK pathway did not mediate the anticancer effect of the triterpenoids UA. 
Unexpectedly, in view of the KRAS mutation, HCT116 cells did not show detectable levels of 
phospho-Akt after 24h of incubation. Probably, a functional PTEN is inhibiting the constitutive 
activation of the PI3K/Akt pathway due to KRAS mutation. Therefore, p-Akt levels were measured 
after 2h of incubation with the extracts/compounds and, although phosphorylation of Akt was 
observed, there were no significant differences when compared with control cells (data not 
shown). These results demonstrated that both PI3K/Akt and MAPK/ERK signalling pathways 
were not involved in the anticancer effects of E. nitens extracts and their main lupane acids. 
The effect of test extracts/compounds on the stress-activated protein kinases p38 and 
JNK was also studied, in view of their involvement in the control of proliferation and induction of 
apoptosis (Ashwell et al., 2006; Dhanasekaram and Reddy, 2011). Although there was no 
significant effects on the phosphorylation levels of p38 (data not shown), both the E. nitens 
extracts and the lupane acids induced p-JNK levels in a concentration-dependent manner (Figure 
18A). Differently from here, a previous work reported that both these kinases were induced in 
melanoma cells treated with BiA (Csuk et al., 2011). However, it was recently shown that the 
triterpenoid UA induced apoptosis through JNK pathway in colorectal cancer cells (Xavier et al., 
2013). Since the tested triterpenoid-enriched extracts and their isolated compounds BiA and BoA 
RESULTS AND DISCUSSION 
 
48 
 
induce JNK signalling more strongly at the higher concentrations where apoptosis occur, it will 
also be interesting in future experiments to check whether apoptosis are dependent on JNK 
activation. These extracts/compounds at higher concentrations may be inducing stress in cells 
that leads to JNK activation that will result in apoptosis through the mitochondrial-caspase 3 
pathway (Weston and Davies, 2007). 
As discussed above, test extracts and compounds at low/intermediate concentrations 
were able to induce non-apoptotic cell death only after 24h of incubation. In fact, at this 
concentrations cells even grow as good as control cells during 24h and then the number of viable 
cells begin to decrease (see Fig. 14 A, C, E & G). Therefore, we asked whether these E. nitens 
extracts, BiA and BoA were inducing some kind of metabolic stress that precipitate cell to die. For 
that, the phosphorylation levels of AMPK were measured by western blot, since this kinase is a 
sensor of cell energy status (AMP/ATP ratio) and plays a fundamental role in the cellular energy 
homeostasis (Inoki et al., 2012). As can be observed in Figure 18A, p-AMPK is markedly 
activated by both extracts/compounds after 24h of incubation, but, interestingly, mostly at 
intermediate concentrations where non-apoptotic cell death occur at later time (Fig. 14 and 
Fig.16). Another observation was that, at these concentrations where non-apoptotic cell death 
occur after 48h and 72h of incubation, cells morphologically lack their shining feature (contrarily 
to control cells) when observed under phase contrast in an inverted microscope. In addition, cells 
easily lose their adherence to the wells with a minimal physical impact, being left floating in the 
medium. With these results, we hypothesise that cells in the presence of low concentrations of 
triterpenoids are able to grow in the first 24h of incubation. Then, after the lacking of some 
important factor in the medium for energy production, cells undergo a reprogramming through 
the metabolic master regulator AMPK, such as by inducing autophagy and inhibiting protein 
synthesis through the mTOR pathway (Inoki et al., 2012), in order to have energy for survival 
under starvations conditions. However, due to some interruption of this survival pathway, the 
AMPK is even more activated but, eventually with the energy loss, the cells end up in a sudden 
death due to a metabolic crisis. Interestingly, it was previously shown that the triterpenoids UA is 
able to inhibit autophagy in colorectal and breast cancer cells (Xavier, 2010; Xavier et al., 2013), 
which is in accordance to the hypothesis outlined above. Furthermore, Duarte (2012) 
demonstrated that the triterpenoids OA induced non-apoptotic cell death in HepG2 cells grown 
under starvation condition, but no significant cell death occurs when grown in complete medium. 
In accordance to the above hypothesis, it was also shown that the transcription factors Sp1, Sp3 
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and Sp4 are downregulated in cells treated with BiA (Chintharlapalli et al., 2011), and, as shown 
here, that the tested extracts/compounds induced a marked loss of p53 levels, which indicates 
that protein synthesis is maybe being interrupted. So, taking all this information into account, we 
can postulate that these intermediate concentrations of extracts/compounds induce mechanisms 
for cell survival, but due to some important defect cells does not even have the machinery to 
programme their death, dying of a metabolic failure. 
 
4. EUCALYPTUS NITENS  EXTRACTS AND THEIR MAIN LUPANE ACIDS INDUCE CELL CYCLE ARREST 
IN HCT116 CELLS 
In order to evaluate if the decrease in the number of viable cells induced by the two E. 
nitens extracts and the two triterpenoids compounds was due to inhibition of cell growth, the cell 
cycle progression was studied by flow cytometry, after 48h of incubation with extracts/ 
compounds. Figure 19A shows that, in general, the extracts and the compounds induced a 
significant G2/M arrest, which indicates their ability to induce cell cycle arrest. However, in most 
of the cases, this effect does not seem to be concentration dependent, probably due to the high 
cell death already present in the higher doses tested. In the particular case of BiA at a 
concentration of 15 µM, besides G2 arrest it was also observed S phase arrest and a significant 
decrease in the percentage of cells at G1/G0 (Fig. 19 A e B). This effect of BiA is in accordance 
with the results reported by Wu et al. (2010) in leukaemia cells. Drag and collaborators (2009) 
reported that cell cycle arrest induced by BiA is dependent of the cell line. Overall, our data in the 
cell cycle arrest induced by the extracts/compounds confirm the results obtained in the anchora-
dependent colony forming (Fig. 14), where we observed an inhibition of colony growth, there is 
colonies contained less cell number as compared with control condition. 
In addition, with the cell cycle analysis, a concentration-dependent increase in the 
percentage of cells at sub-G1 was observed after treating cells for 48h with either one of the E. 
nitens extracts or lupane acids (Figure 19A). This indicates the ability of this extracts/compounds 
to induce DNA fragmentation, which is typical to what happens during apoptosis. These results 
confirmed the higher ability of E. nitens F2 extracts and of BiA to induce cell death by apoptosis 
as compared with E. nitens CE and BoA, respectively, and mainly at higher concentrations 
(Figure 19). 
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Fig.19 – Effect of E. nitens crude extracts (CE), E. nitens fraction 2 (F2), betulinic acid (BiA) and betulonic acid 
(BoA) in the cell cycle of HCT116 cells after 48h of incubation. A) Values are mean ± SEM of at least three 
independent experiments. * P≤0.05, ** P≤0.1, *** P≤0.001, when compared with respective control, analysed by 
the Student’s t-test. B) Representative images of cell cycle analysis in HCT116 cells in a control condition and 
treated for 48h with BiA 15 µM. Shown are cells at sub-G1 (gate F), and divided by the phases of cell cycle: G0/G1 
(gate C), S (gate D) and G2/M (gate E). Clear in the images are the S and G2 arrest induced by BiA as compared 
with control, and a fraction of cell at sub-G1 typical of apoptosis. 
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1. CONCLUSIONS 
The ability to inhibit cell proliferation and to induce apoptosis are two of the major 
characteristics searched in new bioactive drugs for the treatment of cancer. In this study the 
effects of a crude lipophilic extract of E. nitens rich in triterpenic acids, and a fraction of this 
extract (F2) even more enriched in this compound, was studied in HCT116 colorectal cancer 
cells. In addition, two of the major triterpenic constituents of the extracts, the betulinic and 
betulonic acids, were also evaluated for comparison. 
Our findings suggest that all the extracts/compounds tested are biologically active, with 
potent anticancer effects. The E. nitens F2 extract is more potent than the CE, with an IC50 
calculated based on cell viability of 1.3 µg/ml and 2.2 µg/ml, respectively, which correlates, 
therefore, with the extract content in triterpenoids, specially of BiA, BoA and UA. In respect to the 
tested isolated triterpenoids, BoA was shown to be 4 times more active than BoA, with an IC50 of 
0.8 µM and 3.9 µM, respectively. The anticancer potential of the extracts/compounds were 
confirmed by their ability to decrease significantly anchorage-dependent colonies formation and 
to inhibit migration of cells. This latter effect is a very important characteristic to be taken into 
account in cancer, since in later phases of disease development, cancer cells have the tendency 
to migrate from the tumour to metastasize other tissues in the body. 
The anticancer effects of tested extracts/compounds are related in part to their inhibition 
of cell proliferation, since cell cycle arrest was observed. In agreement with that, inhibition of 
colony forming was correlated with the presence of colonies with less number of cells, as 
compared with control. It was also observed that induction of cell death contributes to the 
anticancer effects of the extracts/compounds, since PI-positive cells increase in a concentration 
dependent manner after 24h of incubation. 
Our results also demonstrate that cell death induced by the extracts/compounds are in 
part apoptosis-related, especially at the higher concentrations tested, in view of the presence of 
nuclear condensation and a fraction of cells at sub-G1 phase. Interestingly, comparing the results 
between the lupane acids, although BoA is more potent decreasing cell viability, BiA is more 
potent inducing apoptosis. The apoptosis induced by E. nitens extracts and lupane acids seems 
to be mitochondrial and caspases-dependent, but may not involve p53 (Figure 20), since 
cleavage of caspase 9, caspase 3 and PARP1 was observed accompanied by a decrease of Bcl2 
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levels, whereas p53 levels were remarkably diminished. The PI3K/Akt, MAPK/ERK and p38 
pathways were shown to not be involved in the anticancer effects of the tested 
extracts/compounds. On the other hand, the stress-related kinase JNK was induced in a 
concentration-dependent manner, which may be linked to the p53-independent induction of 
apoptosis by the mitochondrial-caspases pathway (Figure 20). 
However, apoptosis does not explain all the cell death induced by the E. nitens extracts 
and lupane acids. At low/intermediate concentrations, the extracts/compounds induce significant 
cell death that is not dependent in apoptosis, especially for E. nitens extracts and BoA. 
Interestingly, at these concentrations (but not at higher concentrations where apoptosis occurs), 
there was a significant activation of AMPK, as seen by its increased phosphorylation. Therefore, 
activation of this energy-sensing regulator, together with loss of p53, may be an indication of loss 
of energy for proper cell functions, such as for protein synthesis, that ultimately results in a 
metabolic crisis and cell death (Figure 20). 
Fig. 20 – Scheme representing the possible mechanisms of action of the anticancer effect of the triterpenoids-
rich E. nitens  extracts (TREN) and the lupane triterpenoids (LP) betulinic acid and betulonic acid in HCT116 cells. 
MMP – mitochondrial membrane permeabilization. 
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Summing up, the present results describes the potent anticancer effects of lipophilic 
extracts from E. nitens bark in HCT116 colorectal cancer cell, which can be an interesting source 
of bioactive natural triterpenoids used as potent anticancer drugs and/or for the semi-synthesis 
of new improved and more hydrophilic triterpenoids. Being the bark of Eucalyptus one of the 
main byproducts in Portugal from the pulp and paper industry, this work encourages the use of 
these residues to extract added-value compounds and to implement the biorefinery concept in 
their production chain. 
 
2. FUTURE PERSPECTIVES 
With this study it was demonstrated the potential anticancer effects of triterpenoids 
isolated from the bark of Eucalyptus nitens. They were able to trigger apoptosis accompanied by 
activation of the intrinsic mitochondrial-caspase 9 pathway, a decrease of Bcl-2 levels and the 
induction of JNK pathway. In addition, at lower doses, especially BoA was able to induce cell 
death independent of apoptosis and accompanied with the induction of AMPK activity and loss of 
p53. These novel results arise, however, many questions that remain unanswered that should be 
approached in future experiments. 
Although the extracts/compounds induced apoptosis and activation of caspases, the 
present results do not prove that caspases are directly involved in apoptosis. By using 
pharmacological caspases inhibitors, or RNAi against caspases, it will clarify this issue. Also, it 
was hypothesised that apoptosis was triggered by JNK through induction of MMP, which could be 
depicted by using a pharmacological inhibitor against JNK and by measuring the mitochondrial 
membrane potential after treating cells with the E. nitens extracts or triterpenoids. 
Because apoptosis was triggered by the triterpenoids and extracts accompanied with 
reduction of p53 levels, it may indicate that apoptosis was independent of p53. Making the same 
type of experiments in the isogenic HCT116 cells with p53 knockout, or by using RNAi against 
p53, would clarify if this tumour suppressor is really necessary for apoptosis induction by tested 
extracts/compounds. If this hypothesis is correct it is expected that these kind of compounds will 
induce cell death by apoptosis even in resistant cancer cells with p53 mutations, which would be 
an interesting source of anticancer drugs for decreasing cancer chemoresistance. 
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There are some studies that report the ability of some triterpenoids to induce proteasome 
activity, which may explain the decrease in p53 levels in this work and probably other proteins 
(like Sp transcription factors), which can lead to a non-apoptotic type of cell death. So, it would 
be interesting to measure the proteasome activity in the presence of these extracts/compounds 
and to test whether proteasome inhibition would prevent cell death induced by intermediate 
doses of BoA. That would explain the kind of “metabolic death” observed in this study due to a 
chronic degradation of vital proteins. However, the inhibition of their synthesis could be the cause 
of the reduction of these important transcription factors. In fact, AMPK activation, as observed 
here, is known to inhibit mTOR and, therefore, inhibit protein synthesis and to induce autophagy. 
However, it was recently reported that the triterpenoids UA inhibits autophagy at later steps 
(Xavier et al., 2010; Xavier et al., 2012b). If the same happens with BoA, cells would miss the 
acquisition of energy block from recycling cellular molecules, which would lead to a metabolic 
crisis and, eventually, death. This hypothesis should be explored in further experiments. 
To have a broader perspective of its anticancer action, it would also be interesting to 
study the effects of the extracts/compounds in the inhibition of angiogenesis. 
Also, due to the fact that betulinic and betulonic acids are structurally similar to 
cholesterol, those compounds may affect its cellular homeostasis and function, which will affect 
vital cellular processes, some already addressed above. So, investigating this relation could be 
very valuable. 
All these possibilities would help clarify the full potential of the E. nitens bark as source of 
potent anticancer compounds, such as betulinic and betulonic acids. 
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